[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 3066
1. Grochola LF, Greither T, Taubert H, Möller P, Knippschild U, Udelnow A, Henne-Bruns D, Würl P: The stem cell-associated Hiwi gene in human adenocarcinoma of the pancreas: expression and risk of tumour-related death. Br J Cancer; 2008 Oct 7;99(7):1083-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The stem cell-associated Hiwi gene in human adenocarcinoma of the pancreas: expression and risk of tumour-related death.
  • Therefore, we investigated the Hiwi mRNA expression in microdissected PDAC tissues from patients with ductal adenocarcinoma of the pancreas (PDAC) by quantitative real-time PCR and the protein expression by immunohistochemistry.
  • [MeSH-major] Adenocarcinoma / genetics. Neoplastic Stem Cells / metabolism. Pancreatic Neoplasms / genetics. Proteins / genetics

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2001 Jan 15;97(2):426-34 [11154219.001]
  • [Cites] Development. 2008 Apr;135(7):1201-14 [18287206.001]
  • [Cites] Dev Cell. 2002 Jun;2(6):819-30 [12062093.001]
  • [Cites] Curr Probl Cancer. 2002 Jul-Aug;26(4):176-275 [12399802.001]
  • [Cites] Pathol Res Pract. 2003;199(6):431-6 [12924446.001]
  • [Cites] Development. 2004 Feb;131(4):839-49 [14736746.001]
  • [Cites] Genes Dev. 1998 Dec 1;12(23):3715-27 [9851978.001]
  • [Cites] Ann Oncol. 1999;10 Suppl 4:131-5 [10436805.001]
  • [Cites] Neoplasma. 2005;52(6):435-40 [16284686.001]
  • [Cites] Int J Cancer. 2006 Apr 15;118(8):1922-9 [16287078.001]
  • [Cites] Nature. 2006 Jul 13;442(7099):199-202 [16751776.001]
  • [Cites] Oncogene. 2007 Feb 15;26(7):1098-100 [16953229.001]
  • [Cites] PLoS One. 2007;2(3):e293 [17356702.001]
  • [Cites] J Surg Res. 2007 Jun 1;140(1):55-66 [17275032.001]
  • [Cites] Mol Cell. 2007 Jun 8;26(5):603-9 [17560367.001]
  • [Cites] J Surg Res. 2007 Oct;142(2):378-86 [17559882.001]
  • [Cites] Oncogene. 2007 Nov 1;26(50):7170-4 [17525744.001]
  • [Cites] Science. 2007 Nov 2;318(5851):761-4 [17975059.001]
  • [Cites] Nat Rev Mol Cell Biol. 2008 Jan;9(1):22-32 [18073770.001]
  • [Cites] Am J Clin Pathol. 2008 Feb;129(2):211-8 [18208800.001]
  • [Cites] Oncogene. 2002 Jun 6;21(25):3988-99 [12037681.001]
  • (PMID = 18781170.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Argonaute Proteins; 0 / PIWIL1 protein, human; 0 / Proteins; 0 / RNA, Messenger
  • [Other-IDs] NLM/ PMC2567072
  •  go-up   go-down


2. Senderowicz AM, Johnson JR, Sridhara R, Zimmerman P, Justice R, Pazdur R: Erlotinib/gemcitabine for first-line treatment of locally advanced or metastatic adenocarcinoma of the pancreas. Oncology (Williston Park); 2007 Dec;21(14):1696-706; discussion 1706-9, 1712, 1715
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Erlotinib/gemcitabine for first-line treatment of locally advanced or metastatic adenocarcinoma of the pancreas.
  • In this report, we present the pivotal study that led to the approval of erlotinib in combination with gemcitabine (Gemzar) in patients with locally advanced/metastatic chemonaive pancreatic cancer patients.
  • Physicians and patients now have a new option for the treatment of locally advanced/metastatic adenocarcinoma of the pancreas.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Pancreatic Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18247017.001).
  • [ISSN] 0890-9091
  • [Journal-full-title] Oncology (Williston Park, N.Y.)
  • [ISO-abbreviation] Oncology (Williston Park, N.Y.)
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Protein Kinase Inhibitors; 0 / Quinazolines; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; DA87705X9K / Erlotinib Hydrochloride; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


3. Grochola LF, Greither T, Taubert HW, Möller P, Knippschild U, Udelnow A, Henne-Bruns D, Würl P: Prognostic relevance of hTERT mRNA expression in ductal adenocarcinoma of the pancreas. Neoplasia; 2008 Sep;10(9):973-6
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic relevance of hTERT mRNA expression in ductal adenocarcinoma of the pancreas.
  • However, data on hTERT in pancreatic ductal adenocarcinoma (PDAC) are purely descriptive so far.
  • [MeSH-major] Carcinoma, Pancreatic Ductal / genetics. Pancreatic Neoplasms / genetics. Telomerase / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neoplasia. 2003 May-Jun;5(3):193-7 [12869302.001]
  • [Cites] Cell. 2006 Nov 17;127(4):709-20 [17110331.001]
  • [Cites] Pancreas. 2004 Apr;28(3):263-7 [15084968.001]
  • [Cites] J Biol Chem. 1997 May 30;272(22):14183-7 [9162048.001]
  • [Cites] Nat Genet. 1998 Jan;18(1):65-8 [9425903.001]
  • [Cites] Genes Dev. 1998 Jun 15;12(12):1769-74 [9637678.001]
  • [Cites] Neoplasia. 2000 Sep-Oct;2(5):426-32 [11191109.001]
  • [Cites] Neoplasia. 2000 Sep-Oct;2(5):433-40 [11191110.001]
  • [Cites] Cancer Res. 2001 Oct 15;61(20):7594-602 [11606399.001]
  • [Cites] Eur J Surg Oncol. 2001 Dec;27(8):754-60 [11735173.001]
  • [Cites] Oncogene. 2002 Jan 21;21(4):541-52 [11850779.001]
  • [Cites] Lancet. 2002 Mar 16;359(9310):943-5 [11918915.001]
  • [Cites] Curr Probl Cancer. 2002 Jul-Aug;26(4):176-275 [12399802.001]
  • [Cites] Cancer Res. 1998 Sep 15;58(18):4168-72 [9751630.001]
  • [Cites] Clin Cancer Res. 2005 Mar 15;11(6):2285-92 [15788678.001]
  • [Cites] Exp Cell Res. 2005 May 1;305(2):300-11 [15817155.001]
  • [Cites] Oncogene. 2006 Jan 5;25(1):61-9 [16170363.001]
  • [Cites] Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2066-9 [16609017.001]
  • [Cites] Br J Cancer. 2006 May 22;94(10):1452-9 [16641908.001]
  • [Cites] Oncogene. 2006 Sep 21;25(42):5719-25 [16652154.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2007;14(2):189-93 [17384912.001]
  • [Cites] Cell Cycle. 2007 Jun 1;6(11):1284-7 [17534147.001]
  • [Cites] Nature. 2007 Jun 21;447(7147):924-31 [17581575.001]
  • [Cites] J Biol Chem. 2007 Sep 7;282(36):26460-70 [17630431.001]
  • [Cites] Cancer Res. 2007 Oct 1;67(19):9221-8 [17909028.001]
  • [Cites] Oncogene. 2007 Nov 1;26(50):7170-4 [17525744.001]
  • [Cites] Ann Surg. 2007 Dec;246(6):1040-6 [18043108.001]
  • [Cites] Biochimie. 2008 Jan;90(1):13-23 [17854971.001]
  • [Cites] Surgery. 2008 Jan;143(1):113-25 [18154939.001]
  • [Cites] Mol Cell Biol. 2004 Jan;24(1):25-35 [14673140.001]
  • (PMID = 18714398.001).
  • [ISSN] 1476-5586
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / telomerase RNA; 63231-63-0 / RNA; EC 2.7.7.49 / TERT protein, human; EC 2.7.7.49 / Telomerase
  • [Other-IDs] NLM/ PMC2517642
  •  go-up   go-down


Advertisement
4. Izeradjene K, Combs C, Best M, Gopinathan A, Wagner A, Grady WM, Deng CX, Hruban RH, Adsay NV, Tuveson DA, Hingorani SR: Kras(G12D) and Smad4/Dpc4 haploinsufficiency cooperate to induce mucinous cystic neoplasms and invasive adenocarcinoma of the pancreas. Cancer Cell; 2007 Mar;11(3):229-43
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Kras(G12D) and Smad4/Dpc4 haploinsufficiency cooperate to induce mucinous cystic neoplasms and invasive adenocarcinoma of the pancreas.
  • Oncogenic Kras initiates pancreatic tumorigenesis, while subsequent genetic events shape the resultant disease.
  • We show here that concomitant expression of Kras(G12D) and haploinsufficiency of the Smad4/Dpc4 tumor suppressor gene engenders a distinct class of pancreatic tumors, mucinous cystic neoplasms (MCNs), which culminate in invasive ductal adenocarcinomas.
  • Disease evolves along a progression scheme analogous to, but distinct from, the classical PanIN-to-ductal adenocarcinoma sequence, and also portends a markedly different prognosis.
  • Thus, these distinct phenotypic routes to invasive adenocarcinoma nevertheless share the same overall mutational spectra.
  • [MeSH-major] Carcinoma, Pancreatic Ductal / genetics. Cystadenoma, Mucinous / genetics. Genes, ras. Pancreatic Neoplasms / genetics. Smad4 Protein / physiology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17349581.001).
  • [ISSN] 1535-6108
  • [Journal-full-title] Cancer cell
  • [ISO-abbreviation] Cancer Cell
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA15704; United States / NCI NIH HHS / CA / P50 CA62924; United States / NCI NIH HHS / CA / R01 CA101973; United States / NCI NIH HHS / CA / U01 CA084291
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Smad4 Protein; 0 / Smad4 protein, mouse; 0 / Transforming Growth Factor beta; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


5. Zimmermann FB, Jeremic B, Lersch C, Geinitz H, Hennig M, Molls M: Dose escalation of concurrent hypofractionated radiotherapy and continuous infusion 5-FU-chemotherapy in advanced adenocarcinoma of the pancreas. Hepatogastroenterology; 2005 Jan-Feb;52(61):246-50
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dose escalation of concurrent hypofractionated radiotherapy and continuous infusion 5-FU-chemotherapy in advanced adenocarcinoma of the pancreas.
  • BACKGROUND/AIMS: To investigate the advantages and palliative effectiveness of concurrent hypofractionated radiotherapy (RT) and chemotherapy (5-FU) in patients with locally advanced and metastatic adenocarcinoma of the pancreas.
  • CONCLUSIONS: Dose escalation to 36 Gy in a hypofractionated manner proved to be feasible with low toxicity in patients with locally advanced and metastatic adenocarcinoma of the pancreas and warrants further investigation aiming at optimal tailoring in these two subgroups of patients.
  • [MeSH-major] Adenocarcinoma / therapy. Antimetabolites, Antineoplastic / administration & dosage. Dose Fractionation. Fluorouracil / administration & dosage. Pancreatic Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15783041.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  •  go-up   go-down


6. Lygidakis NJ, Jain S, Sacchi M, Vrachnos P: Adenocarcinoma of the pancreas--past, present and future. Hepatogastroenterology; 2005 Jul-Aug;52(64):1281-92
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of the pancreas--past, present and future.
  • Adenocarcinoma of the pancreas has always been a disease with a dismal prognosis.
  • Over the years there has been extensive advancement in the understanding of etiology, molecular biology, diagnosis and treatment of this disease.
  • With the understanding of molecular biology of pancreatic cancer new management strategies are under a preclinical stage of development.
  • These new diagnostic and therapeutic modalities hopefully will improve the outcome of patients with pancreatic cancer.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / therapy. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16001679.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Greece
  • [Number-of-references] 177
  •  go-up   go-down


7. Coklo M, Zamolo G, Petkovic M, Bosnar A, Kukic-Brusic S, Grgurevic E: Sternal metastasis as a first manifestation of adenocarcinoma of the pancreas. Wien Klin Wochenschr; 2005 Sep;117(17):592
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sternal metastasis as a first manifestation of adenocarcinoma of the pancreas.
  • [MeSH-major] Adenocarcinoma / radiography. Adenocarcinoma / secondary. Bone Neoplasms / radiography. Bone Neoplasms / secondary. Pancreatic Neoplasms / radiography. Sternum / radiography

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16395987.001).
  • [ISSN] 0043-5325
  • [Journal-full-title] Wiener klinische Wochenschrift
  • [ISO-abbreviation] Wien. Klin. Wochenschr.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Austria
  •  go-up   go-down


8. Chan M, Scaife C, Thaker HM, Adler DG: Adenocarcinoma of the pancreas undetected by multidetector CT, endoscopic ultrasound, or intraoperative ultrasound. JOP; 2009;10(5):554-6
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of the pancreas undetected by multidetector CT, endoscopic ultrasound, or intraoperative ultrasound.
  • CONTEXT: Patients with known or suspected pancreatic adenocarcinoma are typically evaluated with noninvasive imaging studies and endoscopic ultrasound.
  • Some patients have pancreatic adenocarcinomas that cannot be detected using any of these methods.
  • Multiple endoscopic ultrasound and triple phase pancreatic protocol CT exams were negative for a mass lesion and revealed a normal pancreas.
  • Intraoperative ultrasound of the pancreas was also felt to be normal.
  • Intraoperative biopsy of the head of the pancreas revealed a small, moderately to poorly differentiated adenocarcinoma, not visible on any of her imaging studies.
  • CONCLUSION: Some pancreatic adenocarcinomas may defy detection using modern imaging modalities.
  • [MeSH-major] Adenocarcinoma / diagnosis. Diagnostic Errors. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Cholangiopancreatography, Endoscopic Retrograde / methods. Delayed Diagnosis. Endosonography / methods. Female. Humans. Intraoperative Period. Middle Aged. Tomography, X-Ray Computed / methods. Ultrasonography, Interventional

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19734637.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


9. Königsrainer I, Glatzle J, Klöppel G, Königsrainer A, Wehrmann M: Intraductal and cystic tubulopapillary adenocarcinoma of the pancreas--a possible variant of intraductal tubular carcinoma. Pancreas; 2008 Jan;36(1):92-5
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraductal and cystic tubulopapillary adenocarcinoma of the pancreas--a possible variant of intraductal tubular carcinoma.
  • [MeSH-major] Carcinoma, Pancreatic Ductal / pathology. Pancreatic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18192889.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Keratin-7
  •  go-up   go-down


10. Ito K, Fujita N, Noda Y, Kobayashi G, Kimura K, Horaguchi J, Takasawa O, Kobari M: Intraductal tubular adenocarcinoma of the pancreas diagnosed before surgery by transpapillary biopsy: case report and review. Gastrointest Endosc; 2005 Feb;61(2):325-9
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for tubular adenocarcinoma .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraductal tubular adenocarcinoma of the pancreas diagnosed before surgery by transpapillary biopsy: case report and review.
  • [MeSH-major] Adenocarcinoma / pathology. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15729258.001).
  • [ISSN] 0016-5107
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 25
  •  go-up   go-down


11. Tajiri T, Tate G, Ohike N, Kunimura T, Mitsuya T, Morohoshi T: Sequential progression and intraductal spread of invasive ductal adenocarcinoma of the pancreas arising from around the main pancreatic duct. Hepatogastroenterology; 2005 May-Jun;52(63):745-8
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sequential progression and intraductal spread of invasive ductal adenocarcinoma of the pancreas arising from around the main pancreatic duct.
  • Abdominal contrast computed tomography revealed a mass (20 x 18 mm) in the uncus of the pancreas.
  • Magnetic resonance cholangiopancreatography showed an abrupt narrowing with the dilatation of the peripheral main pancreatic duct (MPD) in the pancreatic head.
  • Histopathological and immunohistochemical examinations led to a diagnosis of sequential progression and intraductal spread of invasive ductal adenocarcinoma of the pancreas arising from around the main pancreaticduct.
  • [MeSH-major] Carcinoma, Pancreatic Ductal / pathology. Pancreatic Ducts / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Aged. Biomarkers, Tumor / analysis. Cholangiopancreatography, Endoscopic Retrograde. Cholangiopancreatography, Magnetic Resonance. Diagnosis, Differential. Disease Progression. Female. Humans. Neoplasm Invasiveness. Pancreas / pathology. Pancreaticoduodenectomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15966196.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


12. Cress RD, Yin D, Clarke L, Bold R, Holly EA: Survival among patients with adenocarcinoma of the pancreas: a population-based study (United States). Cancer Causes Control; 2006 May;17(4):403-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival among patients with adenocarcinoma of the pancreas: a population-based study (United States).
  • OBJECTIVE: The purpose of the current study was to evaluate survival of patients diagnosed in California with adenocarcinoma of the pancreas by demographic and tumor-related factors.
  • METHODS: Through the California Cancer Registry (CCR) we identified all California residents diagnosed with invasive pancreatic adenocarcinoma between 1994 and 2000.
  • CONCLUSIONS: This study is the largest population-based study to date to explore survival from pancreatic cancer among all age groups in a racially diverse population.
  • [MeSH-major] Adenocarcinoma / mortality. Pancreatic Neoplasms / mortality

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16596292.001).
  • [ISSN] 0957-5243
  • [Journal-full-title] Cancer causes & control : CCC
  • [ISO-abbreviation] Cancer Causes Control
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA108370; United States / NCI NIH HHS / CA / CA59706; United States / PHS HHS / / U75-CCU910677
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Netherlands
  •  go-up   go-down


13. Saif MW, Oettle H, Vervenne WL, Thomas JP, Spitzer G, Visseren-Grul C, Enas N, Richards DA: Randomized double-blind phase II trial comparing gemcitabine plus LY293111 versus gemcitabine plus placebo in advanced adenocarcinoma of the pancreas. Cancer J; 2009 Jul-Aug;15(4):339-43
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized double-blind phase II trial comparing gemcitabine plus LY293111 versus gemcitabine plus placebo in advanced adenocarcinoma of the pancreas.
  • BACKGROUND: LY293111 (LY) is a novel oral anticancer agent with leukotriene B4 receptor antagonist and peroxisome proliferator-activated receptor gamma agonist properties, producing promising results alone and in combination with gemcitabine in pancreatic cancer xenograft models.
  • PATIENTS AND METHODS: Chemotherapy-naive patients with histologically confirmed locally advanced or metastatic adenocarcinoma of the pancreas were randomly assigned to gemcitabine 1000 mg/m on days 1, 8, and 15 of a 28-day cycle and continuously administered LY 600 mg twice daily or gemcitabine 1000 mg/m on days 1, 8, and 15 of a 28-day cycle and daily oral placebo.
  • CONCLUSIONS: These results do not demonstrate any benefit to adding LY to gemcitabine in unpretreated patients with advanced pancreatic carcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antimetabolites, Antineoplastic / therapeutic use. Benzoates / therapeutic use. Deoxycytidine / analogs & derivatives. Pancreatic Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19672152.001).
  • [ISSN] 1528-9117
  • [Journal-full-title] Cancer journal (Sudbury, Mass.)
  • [ISO-abbreviation] Cancer J
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Benzoates; 0 / LY 293111; 0 / Receptors, Leukotriene B4; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


14. Ho AS, Huang X, Cao H, Koong AC, Le QT: Detection of circulating hypoxia-regulated miR-210 in pancreatic adenocarcinoma patients. J Clin Oncol; 2009 May 20;27(15_suppl):4624

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of circulating hypoxia-regulated miR-210 in pancreatic adenocarcinoma patients.
  • Moreover, since pancreatic adenocarcinomas have been previously shown to be extremely hypoxic, we hypothesized that miR-210 may be elevated in the plasma of these patients compared to non-cancer controls.
  • Here, we compared the circulating plasma levels of miR-210 in pancreatic cancer patients and controls using a novel miRNA extraction approach and quantitative PCR.
  • METHODS: Pretreatment EDTA plasma samples were obtained from pancreatic cancer patients and age-matched non-cancer controls. miRNA was extracted from 40ul of plasma and reverse transcribed to cDNA.
  • The procedure was performed on the initial 11 pairs of age-matched pancreatic cancer patients and non- cancer controls, then validated with a second cohort of 12 pancreatic cancer patients and 11 controls.
  • There is a statistically significant four-fold increase of mir-210 expression in pancreatic cancer patients compared to normal controls (Student's t-test, p <0.0001).
  • Its expression is significantly higher in the blood of pancreatic cancer patients compared to controls and may potentially serve as a useful biomarker for pancreatic cancer diagnosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964211.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Carr BI, Summers D, Menefee L, Pierpoint S, Yeo C, Kennedy E, Lavu H: Health-related quality of life and pain assessment in 36 patients with resected pancreas adenocarcinoma: Preliminary analysis. J Clin Oncol; 2009 May 20;27(15_suppl):e20692

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Health-related quality of life and pain assessment in 36 patients with resected pancreas adenocarcinoma: Preliminary analysis.
  • : e20692 Background: In order to begin to understand the effects of disease on the patient (pt) and possibly of the pt on the disease, we have begun a systematic psychological inventory of all our pts who have has a pancreatectomy for pancreas adenocarcinoma and have began to correlate this with disease extent, and later with survival.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961756.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Reni M, Cereda S, Aprile G, Tronconi MC, Milandri C, Passoni P, Rognone A, Balzano G, Di Carlo V, Villa E: A randomized phase II trial of adjuvant chemotherapy with cisplatin, epirubicin, 5-fluorouracil, gemcitabine (PEFG regimen) or gemcitabine alone after curative resection for pancreatic cancer. J Clin Oncol; 2009 May 20;27(15_suppl):4608

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized phase II trial of adjuvant chemotherapy with cisplatin, epirubicin, 5-fluorouracil, gemcitabine (PEFG regimen) or gemcitabine alone after curative resection for pancreatic cancer.
  • : 4608 Background: The PEFG regimen yielded a statistically relevant outcome advantage as compared with gemcitabine (G) in patients with advanced pancreatic adenocarcinoma (PA).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964177.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Zacharias T, Jaeck D, Oussoultzoglou E, Neuville A, Bachellier P: Impact of lymph node involvement on long-term survival after R0 pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas. J Gastrointest Surg; 2007 Mar;11(3):350-6
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of lymph node involvement on long-term survival after R0 pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas.
  • Pancreaticoduodenectomy remains the only potentially curative treatment for adenocarcinoma of the pancreas.
  • The aim of this study was to analyze prognostic factors impacting survival after R0 pancreaticoduodenectomy for adenocarcinoma in the head of the pancreas.
  • Between 1995 and 2002, a potentially curative (R0) pancreaticoduodenectomy with pancreatogastrostomy for ductal adenocarcinoma in the head of the pancreas was performed in 81 patients (42 women and 39 men) with a mean age of 64 years (range 35-84).
  • The main risk factor associated with poor survival after an R0 pancreaticoduodenectomy for adenocarcinoma in the head of pancreas was lymph node status: The presence of two or more positive lymph nodes was associated with decreased survival.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma, Pancreatic Ductal / surgery. Pancreatic Neoplasms / surgery. Pancreaticoduodenectomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17458610.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Marten A, Büchler MW, Wente MN, Schmidt J: Soluble iC3b as an early marker for pancreatic adenocarcinoma compared to CA 19.9 and radiology. J Clin Oncol; 2009 May 20;27(15_suppl):4626

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soluble iC3b as an early marker for pancreatic adenocarcinoma compared to CA 19.9 and radiology.
  • : 4626 Background: Pancreatic adenocarcinoma as an aggressive tumor still lacks specific markers.
  • Resection offers the only potential cure, and earlier diagnosis could benefit many patients.
  • Complement regulatory proteins are highly expressed on pancreatic carcinoma cells and detectable in patient's urine.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964206.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Verslype C, Vervenne W, Bennouna J, Humblet Y, Cosaert J, Van Cutsem E: Rash as a marker for the efficacy of gemcitabine plus erlotinib-based therapy in pancreatic cancer: Results from the AViTA Study. J Clin Oncol; 2009 May 20;27(15_suppl):4532

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rash as a marker for the efficacy of gemcitabine plus erlotinib-based therapy in pancreatic cancer: Results from the AViTA Study.
  • : 4532 Background: The EGFR inhibitor, erlotinib (E), in combination with gemcitabine (G), provides a significant survival benefit in metastatic pancreatic cancer.
  • METHODS: Chemo-naïve patients (pts) with metastatic pancreatic adenocarcinoma and KPS of 60-100 were randomized to GE-placebo (GE-P) or GE-B; pts received B/P 5mg/kg q2w plus E (100mg/d) and G (1,000mg/m<sup><sup>2</sup></sup>) given weekly for 7 weeks during the first 8-weekly cycle, followed by weekly for 3 weeks during subsequent 4-weekly cycles.
  • JCO 2007), in pts with advanced pancreatic cancer.
  • Studies are under way to prospectively investigate the relationship between rash and efficacy with erlotinib-based regimens in pancreatic cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962994.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Cohen DJ, Ryan T, Moskovits T, Cazeau N, Newman E, Pachter HL, Hochster HS: Safety and tolerability of combined gemcitabine (G) and erlotinib (E) plus sorafenib (S) in the first-line treatment of metastatic pancreatic cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e15594

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety and tolerability of combined gemcitabine (G) and erlotinib (E) plus sorafenib (S) in the first-line treatment of metastatic pancreatic cancer.
  • : e15594 Background: The addition of E to G results in improved survival for patients(pts) with locally advanced and metastatic pancreatic cancer.
  • Many pancreatic tumors have constitutively activated ras/raf pathways and overexpress VEGF.
  • Sorafenib, a multitargeted tyrosine kinase inhibitor which targets VEGR 1-3, PDGFR-α and β and the RAF/MEK/ERK pathway, when combined with G and E may synergize with these agents resulting in a more complete blockade of the signal transduction cascade in pancreatic cancer growth and progression and therefore improve outcome.
  • METHODS: Pts with previously untreated, histologically confirmed, unresectable pancreatic adenocarcinoma, ECOG PS 0-1, and adequate organ function were eligible and received G 1,000 mg/m<sup>2</sup> over 30 min weekly × 3 every 4 weeks.
  • CONCLUSIONS: The combination of G and E plus S in the treatment of advanced pancreatic cancer is a well tolerated regimen without significant increased toxicity as compared to gemcitabine alone, except for very manageable cutaneous reactions.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962883.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Wong AA, Delclos ME, Wolff RA, Evans DB, Abbruzzese JL, Tamm EP, Xiong HQ, Ho L, Crane CH, Pancreatic Tumor Study Group: Radiation dose considerations in the palliative treatment of locally advanced adenocarcinoma of the pancreas. Am J Clin Oncol; 2005 Jun;28(3):227-33
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiation dose considerations in the palliative treatment of locally advanced adenocarcinoma of the pancreas.
  • Treatment of locally advanced pancreatic cancer with high-dose radiotherapy has not been curative, and can be difficult to tolerate.
  • From December 1993 through May 2001, 107 patients with locally advanced adenocarcinoma of the pancreas had been treated with palliative chemoradiation.
  • Compared with higher doses given over 5 to 6 weeks, chemoradiation (30 Gy in 10 fractions in 2 weeks with concurrent infusional 5-FU) results in a similar median survival, and local disease progression rates in patients with locally advanced pancreatic cancer apparently do not substantially improve local disease control or median survival time.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Palliative Care. Pancreatic Neoplasms / radiotherapy. Radiotherapy, High-Energy

  • MedlinePlus Health Information. consumer health - Palliative Care.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15923793.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA06294; United States / NCI NIH HHS / CA / CA16672
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  •  go-up   go-down


22. Lee J, Lee S, Kim T, Lee J, Park D, Seo D, Lee S, Kim M, Han D, Kim S: Phase II trial of neoadjuvant fixed dose rate (FDR) gemcitabine with capecitabine (GX) combination chemotherapy in locally advanced pancreatic adenocarcinoma (LAPA). J Clin Oncol; 2009 May 20;27(15_suppl):e15553

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of neoadjuvant fixed dose rate (FDR) gemcitabine with capecitabine (GX) combination chemotherapy in locally advanced pancreatic adenocarcinoma (LAPA).
  • : e15553 Background: To determine the efficacy and safety of fixed dose rate (FDR) gemcitabine and capecitaibne (GX) combination chemotherapy for locally advanced pancreatic adenocarcinoma Methods: Patients with histologically confirmed LAPA were eligible for this prospective phase II trial.
  • Dynamic pancreas/pelvic CT, MRI and FDG-PET were undertaken to assess the resectability.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962334.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Yazar A, Ustüner Z, Sakar B, Kaytan Sağlam E, Camlica H, Aykan F: Adjuvant chemoradiation for patients with adenocarcinoma of the pancreas: an expirence of single institute. Med Oncol; 2007;24(4):384-7
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant chemoradiation for patients with adenocarcinoma of the pancreas: an expirence of single institute.
  • Only a small percentage of patients with pancreatic cancer have limited disease suitable for curative resection.
  • We reported the survival of resected pancreatic cancer from a single institute.
  • About 128 consecutive patients who had complete resection of the pancreatic ductal adenocarcinoma were evaluated, retrospectively.
  • Although adjuvant chemoradiotherapy has a significant survival benefit when compared with the observation group, the survival data are still poor for pancreatic cancer.
  • [MeSH-major] Adenocarcinoma / therapy. Pancreatic Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17917086.001).
  • [ISSN] 1357-0560
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Hoffman JP, Stitzenberg KB: Preoperative versus postoperative adjuvant therapy for adenocarcinoma of the pancreas. Adv Surg; 2009;43:189-98
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative versus postoperative adjuvant therapy for adenocarcinoma of the pancreas.
  • Because there have been no RCTs of preoperative and postoperative AT sequencing in the treatment of resectable and borderline resectable pancreatic cancer, it is impossible to assess their relative values with confidence.

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19845178.001).
  • [ISSN] 0065-3411
  • [Journal-full-title] Advances in surgery
  • [ISO-abbreviation] Adv Surg
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 41
  •  go-up   go-down


25. Hwang JY, Yoo C, Kim T, Lee J, Park D, Seo D, Lee S, Kim M, Han D, Kim S, Lee J: A randomized phase II study of FOLFOX or FOLFIRI.3 as second-line therapy in patients with advanced pancreatic cancer previously treated with gemcitabine-based chemotherapy. J Clin Oncol; 2009 May 20;27(15_suppl):4618

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized phase II study of FOLFOX or FOLFIRI.3 as second-line therapy in patients with advanced pancreatic cancer previously treated with gemcitabine-based chemotherapy.
  • : 4618 Background: Only few clinical trials have been conducted in patients with advanced pancreatic cancer after failure of first-line gemcitabine-based chemotherapy.
  • We conducted a randomized phase II trial of modified FOLFOX vs. modified FOLFIRI.3 as second-line regimen for the patients with gemcitabine refractory pancreatic cancer ( NCT00786006 ).
  • METHODS: Patients with advanced pancreatic adenocarcinoma previously treated with gemcitabine were randomly assigned to FOLFOX or FOLFIRI.3 stratifying by age (≤ 65 vs. >65), performance status (0-1 vs. 2) and prior response to gemcitabine (PR/SD vs. PD).
  • CONCLUSIONS: Both FOLFOX and FOLFIRI.3 were tolerated with manageable toxicity, offering modest activity as second-line treatment of patients with advanced or metastatic pancreatic cancer, previously treated with gemcitabine.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964179.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Iott MJ, Corsini MM, Miller RC: Evidence-based guidelines for adjuvant therapy for resected adenocarcinoma of the pancreas. Clin J Oncol Nurs; 2008 Aug;12(4):599-605
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evidence-based guidelines for adjuvant therapy for resected adenocarcinoma of the pancreas.
  • Pancreatic cancer, the fourth most common cause of cancer deaths, has a five-year survival rate of 5% or less.
  • The best adjuvant therapy for patients with resected pancreatic cancer is not clear.
  • The purpose of this article is to review randomized controlled studies of adjuvant chemoradiation or chemotherapy alone in the treatment of resected pancreatic cancer and to determine the optimal adjuvant therapy after curative resection with negative or microscopically positive margins.
  • Three of the four randomized controlled trials suggest that adjuvant chemoradiation for resected pancreatic cancer improves overall survival.
  • Providers counseling patients regarding treatment options for resected pancreatic cancer should continue to recommend adjuvant therapy--a combination of chemotherapy including gemcitabine and radiotherapy--for appropriately selected patients.
  • [MeSH-major] Adenocarcinoma / therapy. Chemotherapy, Adjuvant / standards. Pancreatectomy. Pancreatic Neoplasms / therapy. Practice Guidelines as Topic. Radiotherapy, Adjuvant / standards

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18676327.001).
  • [ISSN] 1092-1095
  • [Journal-full-title] Clinical journal of oncology nursing
  • [ISO-abbreviation] Clin J Oncol Nurs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  • [Number-of-references] 18
  •  go-up   go-down


27. Sa Cunha A, Rault A, Laurent C, Adhoute X, Vendrely V, Béllannée G, Brunet R, Collet D, Masson B: Surgical resection after radiochemotherapy in patients with unresectable adenocarcinoma of the pancreas. J Am Coll Surg; 2005 Sep;201(3):359-65
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical resection after radiochemotherapy in patients with unresectable adenocarcinoma of the pancreas.
  • BACKGROUND: The use of chemoradiotherapy for pancreatic cancer has been advocated for its potential ability to downstage locally advanced tumors.
  • This article reports our experience with chemoradiotherapy for patients with unresectable, locally advanced pancreatic cancer (superior mesenteric artery or celiac axis encasement).
  • STUDY DESIGN: Since 1998, 61 patients with radiographically unresectable, pathologically confirmed pancreatic adenocarcinoma have received standard fractionation radiation therapy (total dose, 45 Gy at 1.8 Gy, 5 d/wk) with chemotherapy, which included a continuous infusion of fluorouracil (5-FU: 650 mg/m(2)/D1-D5 and D21-D25) and cisplatin (80 mg/m(2)/bolus D2 and D22).
  • CONCLUSIONS: Locally advanced, unresectable pancreatic adenocarcinoma may be downstaged by chemoradiotherapy to allow for surgical resection.
  • Patients whose cancer becomes resectable have a median survival at least comparable with survival after resection for initially resectable pancreatic adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / surgery. Adenocarcinoma / therapy. Pancreatic Neoplasms / surgery. Pancreatic Neoplasms / therapy
  • [MeSH-minor] Algorithms. Chemotherapy, Adjuvant. Cisplatin / therapeutic use. Combined Modality Therapy. Fluorouracil / therapeutic use. Follow-Up Studies. Humans. Neoplasm Staging. Palliative Care. Pancreas / pathology. Radiotherapy Dosage. Survival Analysis. Time Factors

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16125068.001).
  • [ISSN] 1072-7515
  • [Journal-full-title] Journal of the American College of Surgeons
  • [ISO-abbreviation] J. Am. Coll. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


28. Motosugi U, Ichikawa T, Yamaguchi H, Nakazawa T, Katoh R, Itakura J, Fujii H, Sato T, Araki T, Shimizu M: Small invasive ductal adenocarcinoma of the pancreas associated with lymphoplasmacytic sclerosing pancreatitis. Pathol Int; 2009 Oct;59(10):744-7
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small invasive ductal adenocarcinoma of the pancreas associated with lymphoplasmacytic sclerosing pancreatitis.
  • An asymptomatic 59-year-old man underwent pancreatoduodenectomy for a pancreatic mass that was discovered during a health check-up.
  • A small invasive ductal adenocarcinoma was observed in the center of the area affected by LPSP.
  • The present case suggests that LPSP may be closely related to carcinogenesis of the pancreas.
  • [MeSH-major] Autoimmune Diseases / pathology. Carcinoma, Pancreatic Ductal / pathology. Pancreas / pathology. Pancreatic Neoplasms / pathology. Pancreatitis, Chronic / pathology

  • Genetic Alliance. consumer health - Pancreatitis.
  • MedlinePlus Health Information. consumer health - Autoimmune Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19788620.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Immunoglobulin G
  •  go-up   go-down


29. Vachiranubhap B, Kim YH, Balci NC, Semelka RC: Magnetic resonance imaging of adenocarcinoma of the pancreas. Top Magn Reson Imaging; 2009 Feb;20(1):3-9
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnetic resonance imaging of adenocarcinoma of the pancreas.
  • Magnetic resonance imaging (MRI) is a valuable tool in the assessment of the full spectrum of pancreatic disease.
  • A standard MR protocol including noncontrast T1-weighted fat-suppressed and dynamic gadolinium-enhanced gradient-echo imagings is sensitive for the evaluation of pancreatic cancer.
  • Optimal use of MRI in the investigation of pancreatic cancer occurs in the following circumstances:.
  • The objective of this study was to describe the attribute of MRI for evaluating pancreatic cancer.
  • [MeSH-major] Carcinoma, Pancreatic Ductal / diagnosis. Cholangiopancreatography, Magnetic Resonance / methods. Cholangiopancreatography, Magnetic Resonance / trends. Image Enhancement / methods. Pancreas / pathology. Pancreatic Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19687720.001).
  • [ISSN] 1536-1004
  • [Journal-full-title] Topics in magnetic resonance imaging : TMRI
  • [ISO-abbreviation] Top Magn Reson Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 32
  •  go-up   go-down


30. Plate JM, Plate AE, Shott S, Bograd S, Harris JE: Effect of gemcitabine on immune cells in subjects with adenocarcinoma of the pancreas. Cancer Immunol Immunother; 2005 Sep;54(9):915-25
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of gemcitabine on immune cells in subjects with adenocarcinoma of the pancreas.
  • Effects of gemcitabine (Gemzar) on immune cells were examined in pancreas cancer patients to determine whether it was immunosuppressive, or potentially could be combined with vaccines or other immunotherapy to enhance patient's responses to their tumors.
  • Immune T-cells were functional in pancreas cancer patients treated with gemcitabine.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Deoxycytidine / analogs & derivatives. Lymphocyte Activation / drug effects. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / immunology. T-Lymphocytes
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / immunology. Adenocarcinoma / secondary. Aged. Aged, 80 and over. Antigen-Presenting Cells / immunology. B-Lymphocytes / immunology. B-Lymphocytes / metabolism. CD4-CD8 Ratio. Dendritic Cells / immunology. Dendritic Cells / metabolism. Female. Humans. Killer Cells, Natural / immunology. Killer Cells, Natural / metabolism. Male. Middle Aged. Ribonucleotide Reductases / antagonists & inhibitors

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15782312.001).
  • [ISSN] 0340-7004
  • [Journal-full-title] Cancer immunology, immunotherapy : CII
  • [ISO-abbreviation] Cancer Immunol. Immunother.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; EC 1.17.4.- / Ribonucleotide Reductases
  •  go-up   go-down


31. Maréchal R, Demetter P, Berton A, Salmon I, Van Laethem J: Correlation of CXCR4 expression in resected pancreatic adenocarcinoma (PA) with relapse and survival after adjuvant radiochemotherapy (RCT). J Clin Oncol; 2009 May 20;27(15_suppl):e22022

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of CXCR4 expression in resected pancreatic adenocarcinoma (PA) with relapse and survival after adjuvant radiochemotherapy (RCT).
  • This chemoreceptor could be implicated in the resistance of pancreatic cancer cells to RCT and its targeted inhibition deserves clinical evaluation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963130.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Oh D, Lee K, Lee K, Sohn C, Park Y, Zang D, Ryoo H, Bang Y: A phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer: Combined analysis with translational research. J Clin Oncol; 2009 May 20;27(15_suppl):4607

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer: Combined analysis with translational research.
  • : 4607 Background: To confirm the efficacy and toxicity of erlotinib (E) in combination with gemcitabine (G) and capecitabine (C) when used as a first-line therapy in patients (pts) with metastatic/recurrent pancreatic cancer Methods: Pts with advanced pancreatic adenocarcinoma, with measurable lesion were eligible for the study.
  • Locally advanced pancreatic cancer was excluded.
  • CONCLUSIONS: Erlotinib in combination with gemcitabine and capecitabine showed promising efficacy and good tolerability in metastatic pancreatic cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964140.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Von Hoff DD, Ramanathan R, Borad M, Laheru D, Smith L, Wood T, Korn R, Desai N, Iglesias J, Hidalgo M: SPARC correlation with response to gemcitabine (G) plus nab-paclitaxel (nab-P) in patients with advanced metastatic pancreatic cancer: A phase I/II study. J Clin Oncol; 2009 May 20;27(15_suppl):4525

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] SPARC correlation with response to gemcitabine (G) plus nab-paclitaxel (nab-P) in patients with advanced metastatic pancreatic cancer: A phase I/II study.
  • : 4525 Background: Pancreatic cancer cells and surrounding stroma are known to overexpress SPARC (secreted protein acid rich in cysteine), which is associated with poor clinical outcomes. nab-P, an albumin-bound nanoparticle form of paclitaxel increased tumor accumulation of paclitaxel through binding of albumin to SPARC.
  • METHODS: nab-P doses (100-150 mg/m<sup>2</sup>) + (G) (1000 mg/m<sup>2</sup>) were given on days 1, 8, and 15 of a 28-day cycle to pts with metastatic pancreatic adenocarcinoma and with no prior chemotherapy for their metastatic disease.
  • CONCLUSIONS: The combination of nab-P and G was generally well tolerated and had substantial enough antitumor activity in patients with pancreatic cancer to warrant a phase III clinical trial.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962720.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Thieltges S, Kalinina T, Krohn A, Simon R, Moeller-Krull M, Dierlamm J, Izbicki J, Yekebas E: Identification of chromosomal regions that harbor novel genes important for pancreatic cancer pathogenesis by genome-wide screening methods. J Clin Oncol; 2009 May 20;27(15_suppl):e15609

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of chromosomal regions that harbor novel genes important for pancreatic cancer pathogenesis by genome-wide screening methods.
  • : e15609 Background: Pancreatic adenocarcinoma is a genetically highly complex and heterogenous tumor type with strong genetic instability which makes it resistant to therapy.
  • METHODS: We report the use of an Affymetrix Genome-Wide Human single nucleotide polymorphism (SNP) Array 6.0 (906,600 SNPs) to screen for gene copy number changes and allelic imbalances in 8 microdissected primary pancreatic tumors and 7 established pancreatic cancer cell lines.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962682.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Ishii H, Furuse J, Boku N, Okusaka T, Ikeda M, Ohkawa S, Fukutomi A, Hamamoto Y, Nakamura K, Fukuda H: Phase II study of gemcitabine chemotherapy alone for locally advanced pancreatic carcinoma: JCOG 0506. J Clin Oncol; 2009 May 20;27(15_suppl):e15578

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of gemcitabine chemotherapy alone for locally advanced pancreatic carcinoma: JCOG 0506.
  • : e15578 Background: Fluorouracil (5-FU) chemoradiotherapy has been accepted as standard care for locally advanced pancreatic cancer (LAPC); however, it has not been shown to be superior to chemotherapy alone in gemcitabine (Gem) era.
  • METHODS: Eligibility criteria included the following: patients (pts) with histologically or cytologically proven pancreatic adenocarcinoma or adenosquamous carcinoma, pts with UICC clinical stage III (T4N0-1 and M0), all lesions are assumed to be included in the radiation field of 15 cm square, age 20 or older, no prior treatment for LAPC, ECOG performance status of 0, 1 or 2, and adequate organ function.
  • Patient characteristics were: median age; 67.5 (45-80), male/female; 35/15, PS 0/1/2; 30/20/0, pancreatic head/body-tail; 26/24.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962370.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Capdevila J, Clive S, Tabernero J, Lardelli P, Soto-Matos A, Baselga J, Piera A, Pardos I, Rye R, Smyth JF: Phase I study of the novel anticancer drug PM00104 as a 24-hour IV infusion every 3 weeks (q3w) in patients (pts) with advanced solid tumors or lymphoma. J Clin Oncol; 2009 May 20;27(15_suppl):2568

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • No objective responses were seen but 3 pts with pancreatic adenocarcinoma, hepatocarcinoma and lower esophagus adenocarcinoma presented stable disease lasting >3 months.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961881.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA008748
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Kazanjian KK, Hines OJ, Duffy JP, Yoon DY, Cortina G, Reber HA: Improved survival following pancreaticoduodenectomy to treat adenocarcinoma of the pancreas: the influence of operative blood loss. Arch Surg; 2008 Dec;143(12):1166-71
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improved survival following pancreaticoduodenectomy to treat adenocarcinoma of the pancreas: the influence of operative blood loss.
  • HYPOTHESIS: Although the safety of pancreaticoduodenectomy has notably improved over the past several decades, the reported survival of patients with pancreatic cancer remains poor.
  • We hypothesized that, in recent years, the survival of patients with pancreatic adenocarcinoma following pancreaticoduodenectomy has substantially improved.
  • SETTING: Major academic medical and pancreatic surgery center.
  • INTERVENTIONS: Pancreaticoduodenectomy for patients with a diagnosis of pancreatic adenocarcinoma.
  • RESULTS: During the time period analyzed, 182 patients underwent pancreaticoduodenectomy to treat ductal adenocarcinoma.
  • CONCLUSIONS: The survival rate for patients undergoing pancreaticoduodenectomy to treat pancreatic cancer has substantially improved.
  • [MeSH-major] Adenocarcinoma / surgery. Blood Loss, Surgical / mortality. Pancreatic Neoplasms / surgery. Pancreaticoduodenectomy / mortality

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Arch Surg. 2009 Jun;144(6):594; author reply 594-5 [19528398.001]
  • (PMID = 19075167.001).
  • [ISSN] 1538-3644
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Paklina OV, Setdikova GR: [Immunohistochemical study of mucins in chronic pancreatitis and ductal adenocarcinoma of the pancreas]. Arkh Patol; 2008 Jul-Aug;70(4):13-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Immunohistochemical study of mucins in chronic pancreatitis and ductal adenocarcinoma of the pancreas].
  • Based on the results of an immunohistological study of MUC1, MUC2, MUC4, MUC5AC, and MUC6 in pancreatic tissue from 50 patients with chronic pancreatitis (CP) and 50 patients with ductal adenocarcinoma (DAC), the authors showed altered mucin immunological responsiveness in severe forms of CP, in the foci of PanIN and DAC.
  • They also revealed that determination of mucin expression may be used in the differential diagnosis of pancreatic cancer.
  • [MeSH-major] Carcinoma, Pancreatic Ductal / metabolism. Mucins / metabolism. Neoplasm Proteins / metabolism. Pancreatic Neoplasms / metabolism. Pancreatitis, Chronic / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Retrospective Studies


39. de Castro SM, Biere SS, Lagarde SM, Busch OR, van Gulik TM, Gouma DJ: Validation of a nomogram for predicting survival after resection for adenocarcinoma of the pancreas. Br J Surg; 2009 Apr;96(4):417-23
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Validation of a nomogram for predicting survival after resection for adenocarcinoma of the pancreas.
  • The pancreatic nomogram, originally developed in the Memorial Sloan-Kettering Cancer Center (MSKCC) in the USA, combines clinicopathological and operative data to predict disease-specific survival at 1, 2 and 3 years from initial resection.
  • METHODS: An external patient cohort from a retrospective pancreatic adenocarcinoma database at the Academic Medical Centre in Amsterdam was used to test the validity of the pancreatic adenocarcinoma nomogram.
  • CONCLUSION: The MSKCC pancreatic cancer nomogram provided an accurate survival prediction.
  • [MeSH-major] Adenocarcinoma / surgery. Nomograms. Pancreatic Neoplasms / surgery. Prostatic Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.
  • (PMID = 19283741.001).
  • [ISSN] 1365-2168
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Validation Studies
  • [Publication-country] England
  •  go-up   go-down


40. Mackenzie RP, McCollum AD: Novel agents for the treatment of adenocarcinoma of the pancreas. Expert Rev Anticancer Ther; 2009 Oct;9(10):1473-85
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel agents for the treatment of adenocarcinoma of the pancreas.
  • Pancreatic cancer is a particularly challenging malignancy, given its usually advanced stage at diagnosis and its rather limited treatment options.
  • Gemcitabine has been standard therapy for advanced pancreatic cancer for well over a decade.
  • Continued research is clearly warranted with the goal of improving survival and optimizing treatment outcomes in locally advanced and metastatic pancreatic cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / therapeutic use. Pancreatic Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19828009.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  • [Number-of-references] 111
  •  go-up   go-down


41. Turrini O, Ychou M, Moureau-Zabotto L, Rouanet P, Giovannini M, Moutardier V, Azria D, Delpero JR, Viret F: Neoadjuvant docetaxel-based chemoradiation for resectable adenocarcinoma of the pancreas: New neoadjuvant regimen was safe and provided an interesting pathologic response. Eur J Surg Oncol; 2010 Oct;36(10):987-92
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant docetaxel-based chemoradiation for resectable adenocarcinoma of the pancreas: New neoadjuvant regimen was safe and provided an interesting pathologic response.
  • PURPOSE: To assess the safety and efficacy of a new neoadjuvant chemoradiation (CRT) docetaxel-based regimen in patients with resectable adenocarcinoma of the pancreatic head or body.
  • PATIENTS AND METHODS: 34 patients with histologically-confirmed resectable pancreatic adenocarcinoma were included in this prospective two-center phase II study.
  • Among the resected patients, ten (59%) died as a result of recurrent pancreatic cancer without local tumor bed recurrence.
  • [MeSH-major] Adenocarcinoma / mortality. Adenocarcinoma / therapy. Neoadjuvant Therapy. Pancreatic Neoplasms / mortality. Pancreatic Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010. Published by Elsevier Ltd.
  • (PMID = 20828979.001).
  • [ISSN] 1532-2157
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel
  •  go-up   go-down


42. Hristov B, Reddy S, Lin SH, Cameron JL, Pawlik TM, Hruban RH, Swartz MJ, Edil BH, Kemp C, Wolfgang CL, Herman JM: Outcomes of adjuvant chemoradiation after pancreaticoduodenectomy with mesenterico-portal vein resection for adenocarcinoma of the pancreas. Int J Radiat Oncol Biol Phys; 2010 Jan 1;76(1):176-80
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes of adjuvant chemoradiation after pancreaticoduodenectomy with mesenterico-portal vein resection for adenocarcinoma of the pancreas.
  • PURPOSE: Surgery followed by chemotherapy and radiation (CRT) offers patients with pancreatic adenocarcinoma a chance for extended survival.
  • The purpose of this study was to compare outcomes between pancreaticoduodenectomy (PD) with and without mesenterico-portal vein resection (VR) in patients receiving adjuvant CRT for pancreatic adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / therapy. Mesenteric Veins / surgery. Pancreatic Neoplasms / therapy. Pancreaticoduodenectomy / methods. Portal Vein / surgery

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19394156.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  •  go-up   go-down


43. Brown KM, Domin C, Aranha GV, Yong S, Shoup M: Increased preoperative platelet count is associated with decreased survival after resection for adenocarcinoma of the pancreas. Am J Surg; 2005 Mar;189(3):278-82
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased preoperative platelet count is associated with decreased survival after resection for adenocarcinoma of the pancreas.
  • However, the relationship between platelet count and prognosis in pancreatic cancer remains unresolved.
  • METHODS: A chart review of patients undergoing resection for pancreatic adenocarcinoma was undertaken.
  • RESULTS: Between June 1995 and March 2003, 109 patients (63% male) with a median age of 68 years (range 42 to 85 years) underwent resection for pancreatic cancer.
  • CONCLUSIONS: Increased preoperative platelet count is associated with adverse survival outcome in patients undergoing resection for pancreatic cancer.
  • [MeSH-major] Adenocarcinoma / blood. Adenocarcinoma / mortality. Pancreatic Neoplasms / blood. Pancreatic Neoplasms / mortality. Platelet Count

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15792750.001).
  • [ISSN] 0002-9610
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Poultsides GA, Reddy S, Cameron JL, Hruban RH, Pawlik TM, Ahuja N, Jain A, Edil BH, Iacobuzio-Donahue CA, Schulick RD, Wolfgang CL: Histopathologic basis for the favorable survival after resection of intraductal papillary mucinous neoplasm-associated invasive adenocarcinoma of the pancreas. Ann Surg; 2010 Mar;251(3):470-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histopathologic basis for the favorable survival after resection of intraductal papillary mucinous neoplasm-associated invasive adenocarcinoma of the pancreas.
  • OBJECTIVE: To identify pathologic features that may account for the favorable survival after resection of invasive pancreatic adenocarcinoma arising in the setting of intraductal papillary mucinous neoplasm (IPMN) compared with standard pancreatic ductal adenocarcinoma (PDA) in the absence of IPMN.
  • SUMMARY BACKGROUND DATA: The 5-year survival after resection of IPMN-associated invasive adenocarcinoma is reported to be between 40% and 60%, which is superior to the 10-25%, typically cited after resection of standard PDA.
  • It remains unclear whether this represents distinct biology or simply a tendency for earlier presentation of IPMN-associated invasive adenocarcinoma.
  • METHODS: A single institution's prospective pancreatic resection database was retrospectively reviewed to identify patients with invasive pancreatic adenocarcinoma who underwent pancreatectomy with curative intent.
  • RESULTS: From 1995 to 2006, 1260 consecutive patients were identified, 132 (10%) with IPMN-associated invasive adenocarcinoma and 1128 (90%) with standard PDA.
  • However, compared with standard PDA, invasive adenocarcinoma arising within an IPMN was associated with a lower incidence of (1) advanced T stage (T2-T4, 96% vs. 73%, P < 0.001);.
  • In the presence of any one of the aforementioned adverse pathologic characteristics, however, survival outcomes after resection of IPMN-associated and after resection of standard pancreatic adenocarcinoma are similar.
  • [MeSH-major] Adenocarcinoma, Mucinous / mortality. Adenocarcinoma, Mucinous / pathology. Pancreatic Neoplasms / mortality. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2000 Apr 1;60(7):1835-9 [10766168.001]
  • [Cites] Ann Surg. 2009 Mar;249(3):440-7 [19247032.001]
  • [Cites] Am J Surg Pathol. 2001 Jan;25(1):26-42 [11145249.001]
  • [Cites] Ann Surg. 2001 Sep;234(3):313-21; discussion 321-2 [11524584.001]
  • [Cites] Am J Surg Pathol. 2002 Jan;26(1):56-63 [11756769.001]
  • [Cites] Gut. 2002 Nov;51(5):717-22 [12377813.001]
  • [Cites] Carcinogenesis. 2003 Feb;24(2):193-8 [12584167.001]
  • [Cites] Am J Surg Pathol. 2003 May;27(5):571-8 [12717243.001]
  • [Cites] Ann Surg. 2004 Mar;239(3):400-8 [15075659.001]
  • [Cites] Ann Surg. 2004 May;239(5):678-85; discussion 685-7 [15082972.001]
  • [Cites] Ann Surg. 2004 Jun;239(6):788-97; discussion 797-9 [15166958.001]
  • [Cites] Am J Surg Pathol. 2004 Jul;28(7):839-48 [15223952.001]
  • [Cites] Am J Surg Pathol. 2004 Aug;28(8):977-87 [15252303.001]
  • [Cites] Ann Surg. 1996 Mar;223(3):273-9 [8604907.001]
  • [Cites] Am J Surg. 2005 May;189(5):632-6; discussion 637 [15862510.001]
  • [Cites] Ann Surg Oncol. 2006 Apr;13(4):582-94 [16523362.001]
  • [Cites] Clin Cancer Res. 2006 Jun 15;12(12):3851-5 [16778113.001]
  • [Cites] J Gastrointest Surg. 2006 Nov;10(9):1199-210; discussion 1210-1 [17114007.001]
  • [Cites] Ann Surg. 2007 Jul;246(1):52-60 [17592291.001]
  • [Cites] Arch Surg. 2008 Jul;143(7):639-46; discussion 646 [18645105.001]
  • [Cites] Am J Pathol. 2000 Sep;157(3):755-61 [10980115.001]
  • (PMID = 20142731.001).
  • [ISSN] 1528-1140
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA140599; United States / NCI NIH HHS / CA / R01 CA140599-01; United States / NCI NIH HHS / CA / R01 CA140599-02; United States / NCI NIH HHS / CA / R01 CA140599-03
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS264358; NLM/ PMC3437748
  •  go-up   go-down


45. Sams VG, Akin HE: Umbilical Hernia Repair in Patient with Ascites with Incidental Finding of Pancreatic Adenocarcinoma Metastasis in Hernia Sac. Am Surg; 2010 Aug 01;76(8):144-145

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Umbilical Hernia Repair in Patient with Ascites with Incidental Finding of Pancreatic Adenocarcinoma Metastasis in Hernia Sac.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28958238.001).
  • [ISSN] 1555-9823
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Maximous D, Abdel-Wanis ME, Aboziada MA, El-Sayed MI, Abd-Elsayed AA: Preoperative gemcitabine based chemoradiotherapy in locally advanced nonmetastatic pancreatic adenocarcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):e15677

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative gemcitabine based chemoradiotherapy in locally advanced nonmetastatic pancreatic adenocarcinoma.
  • : e15677 Background: Almost 30% of patients with pancreatic cancer present with locally advanced tumours in absence of distant metastasis.
  • The combination of gemcitabine with concurrent radiation therapy is a promising approach that is being investigated in patients' unresectable pancreatic cancer.
  • AIM OF THE WORK: The efficacy of preoperative gemcitabine based chemo-radiotherapy in increasing the resectability rate for patients locally advanced, non metastatic pancreatic cancer was assessed.
  • CONCLUSIONS: preoperative gemcitabine based chemoradiation might benefit patients with locally advanced non metastatic pancreatic cancer by increasing the resectability without significant acute toxicity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962829.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Colucci G, Labianca R, Di Costanzo F, Gebbia V, Cartenì G, Massidda B, Frontini L, Falconi M, Gallo C, Di Maio M: A randomized trial of gemcitabine (G) versus G plus cisplatin in chemotherapy-naive advanced pancreatic adenocarcinoma: The GIP-1 (Gruppo Italiano Pancreas- GOIM/GISCAD/GOIRC) study. J Clin Oncol; 2009 May 20;27(15_suppl):4504

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized trial of gemcitabine (G) versus G plus cisplatin in chemotherapy-naive advanced pancreatic adenocarcinoma: The GIP-1 (Gruppo Italiano Pancreas- GOIM/GISCAD/GOIRC) study.
  • : 4504 Background: Single-agent gemcitabine (G) remains standard treatment for advanced pancreatic adenocarcinoma (APC).
  • METHODS: Patients (pts) with locally advanced and/or metastatic pancreatic adenocarcinoma, age 18-75, Karnofsky Performance Status (KPS) ≥50, were randomized to receive G (arm A) or G+P (arm B).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962688.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Fine R, Moorer G, Sherman W, Chu K, Maurer M, Chabot J, Postolov I, Prowda J, Schreibman S, Levitz J: Phase II trial of GTX chemotherapy in metastatic pancreatic cancer. J Clin Oncol; 2009 May 20;27(15_suppl):4623

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of GTX chemotherapy in metastatic pancreatic cancer.
  • This GTX regimen was designed to inhibit MEK-ERK phosphorylation and increase BAX and BAK and also decrease BCL-2 in pancreatic cancer cell lines.
  • Based on these findings, we pursued a prospective clinical trial evaluating the activity of GTX in previously untreated patients with metastatic pancreatic cancer.
  • METHODS: Patients with histologically confirmed metastatic adenocarcinoma of the pancreas, median age 60, 63% male, ECOG PS 0-2, received capecitabine 1500mg/m2/day total orally in divided doses, days 1 thru 14, gemcitabine 750mg/m2 IV over 75 minutes followed by docetaxel 30mg/m2 IV on days 4 and 11 on a 21 day cycle.
  • CONCLUSIONS: The combination of gemcitabine, docetaxel, and capecitabine has activity in metastatic pancreatic cancer with a median survival over 1 year.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964215.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Bonnetain F, Maillard E, Seitz J, Mitry E, Ychou M, Gasmi M, Raoul J, Mariette C, Bedenne L, Dahan L: Longitudinal analysis of quality of life (QoL) within a randomized phase III trial in patients (pts) with metastatic pancreatic adenocarcinoma (MPA). J Clin Oncol; 2009 May 20;27(15_suppl):e17544

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Longitudinal analysis of quality of life (QoL) within a randomized phase III trial in patients (pts) with metastatic pancreatic adenocarcinoma (MPA).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963761.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


50. Dahan L, Methy N, Seitz J, Mitry E, Ychou M, Gasmi M, Raoul J, Mariette C, Bedenne L, Bonnetain F: Impact of first-line and second-line PFS definitions within a randomized phase III trial in patients (pts) with metastatic pancreatic adenocarcinoma (MPA). J Clin Oncol; 2009 May 20;27(15_suppl):e15583

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of first-line and second-line PFS definitions within a randomized phase III trial in patients (pts) with metastatic pancreatic adenocarcinoma (MPA).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962358.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Ulusan S, Yakar T, Koc Z, Kayaselcuk F, Torer N: Adenocarcinoma of the pancreas associated with dorsal agenesis. Pancreas; 2006 Nov;33(4):437-9
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of the pancreas associated with dorsal agenesis.
  • [MeSH-major] Adenocarcinoma / pathology. Liver Neoplasms / secondary. Pancreas / abnormalities. Pancreatic Neoplasms / pathology

  • Genetic Alliance. consumer health - Pancreas agenesis, dorsal.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17079954.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  •  go-up   go-down


52. Limmathurotsakul D, Rerknimitr P, Korkij W, Noppakun N, Kullavanijaya P, Rerknimitr R: Metastatic mucinous cystic adenocarcinoma of the pancreas presenting as Sister Mary Joseph's nodule. JOP; 2007;8(3):344-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic mucinous cystic adenocarcinoma of the pancreas presenting as Sister Mary Joseph's nodule.
  • CONTEXT: Sister Mary Joseph's nodule usually represents metastatic cancers from gastrointestinal malignancy including adenocarcinoma of the pancreas.
  • Mucinous cystadenocarcinoma is a rare malignancy of the pancreas.
  • However, pancreatic mucinous cystadenocarcinoma metastasized to Sister Mary Joseph's nodule is much rarer and has never been reported before.
  • A CT scan showed a large cystic lesion with internal septation at the pancreatic tail.
  • CONCLUSION: To our knowledge, this is the first report of pancreatic mucinous cystadenocarcinoma metastasized as Sister Mary Joseph's nodule.
  • [MeSH-major] Cystadenocarcinoma, Mucinous / pathology. Cystadenocarcinoma, Mucinous / secondary. Pancreatic Neoplasms / pathology. Skin Neoplasms / secondary. Umbilicus / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17495365.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / CA-19-9 Antigen; 0 / Carcinoembryonic Antigen
  •  go-up   go-down


53. Hayano K, Asano T, Amano H, Miura F, Toyota N, Wada K, Kato K, Shibuya M, Kadowaki S, Maeno S, Takada T: Huge mucinous cystic adenocarcinoma of the pancreas. Dig Surg; 2010;27(6):467-8
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Huge mucinous cystic adenocarcinoma of the pancreas.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Pancreatic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21063122.001).
  • [ISSN] 1421-9883
  • [Journal-full-title] Digestive surgery
  • [ISO-abbreviation] Dig Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


54. Hara H, Suda K, Oyama T: Two cytologic patterns in invasive ductal adenocarcinoma of the pancreas. Acta Cytol; 2005 Nov-Dec;49(6):611-20

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two cytologic patterns in invasive ductal adenocarcinoma of the pancreas.
  • OBJECTIVE: To clarify 2 cytologic patterns: severe ductal dysplasia (SD)/carcinoma in situ (CIS) and invasive components of invasive ductal adenocarcinoma of the pancreas (IDAP).
  • [MeSH-major] Carcinoma, Pancreatic Ductal / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16450900.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


55. Cereda S, Rognone A, Ghidini M, Rezzonico S, Passoni P, Mazza E, Nicoletti R, Zerbi A, Villa E, Reni M: A randomized phase II trial of two different four-drug combinations in advanced pancreatic adenocarcinoma: Cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel. J Clin Oncol; 2009 May 20;27(15_suppl):4614

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized phase II trial of two different four-drug combinations in advanced pancreatic adenocarcinoma: Cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel.
  • : 4614 Background: The combination of cisplatin (P), epirubicin (E), 5-fluorouracil (F) and gemcitabine (G) (PEFG regimen) yielded a progression-free survival at 6 months from treatment start (PFS6) of about 50% and a 1-year overall survival (OS) around 40% in patients with advanced pancreatic adenocarcinoma (PA).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964185.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


56. Kowalski J, Morsberger LA, Blackford A, Hawkins A, Yeo CJ, Hruban RH, Griffin CA: Chromosomal abnormalities of adenocarcinoma of the pancreas: identifying early and late changes. Cancer Genet Cytogenet; 2007 Oct 1;178(1):26-35
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chromosomal abnormalities of adenocarcinoma of the pancreas: identifying early and late changes.
  • Derivation of such pathways in adenocarcinoma of the pancreas has been particularly limited, because only a few pancreatic carcinomas are resected at an early stage of disease and so the number of primary carcinomas for which analysis of abnormal karyotypes has been reported is small.
  • Here we report the clonal karyotypic abnormalities identified by G-banding analysis of 36 primary pancreatic carcinomas obtained from patients undergoing a Whipple resection with curative intent.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Chromosome Aberrations. Pancreatic Neoplasms / genetics. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17889705.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA62924
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


57. Chang DT, Schellenberg D, Shen J, Kim J, Goodman KA, Fisher GA, Ford JM, Desser T, Quon A, Koong AC: Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas. Cancer; 2009 Feb 1;115(3):665-72
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas.
  • BACKGROUND: The authors report on the local control and toxicity of stereotactic body radiotherapy (SBRT) for patients with unresectable pancreatic adenocarcinoma.
  • METHODS: Seventy-seven patients with unresectable adenocarcinoma of the pancreas received 25 gray (Gy) in 1 fraction.
  • CONCLUSIONS: SBRT for pancreatic adenocarcinoma was effective for local control with associated risk of toxicity and should be used with rigorous attention to quality assurance.
  • [MeSH-major] Adenocarcinoma / surgery. Pancreatic Neoplasms / surgery. Radiosurgery

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 American Cancer Society.
  • [CommentIn] Cancer. 2009 Feb 1;115(3):468-72 [19117338.001]
  • (PMID = 19117351.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


58. Mazzer M, Zanon E, Foltran L, De Pauli F, Cardellino G, Iaiza E, Ermacora P, Aprile G, Fasola G: Second-line pemetrexed-oxaliplatin combination for advanced pancreatic adenocarcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):e15597

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second-line pemetrexed-oxaliplatin combination for advanced pancreatic adenocarcinoma.
  • : e15597 Background: Few regimens showed efficacy in advanced pancreatic cancer patients (pts) who had failed a first-line gemcitabine-based therapy.
  • METHODS: Pancreatic cancer pts with advanced disease, PS>60, age>18 years, who progressed after a gemcitabine-based therapy were enrolled in a phase II trial, and treated with pemetrexed 500 mg/mq followed by oxaliplatin 120 mg/mq, day 1 every 3 weeks, together with adequate oral folinic acid and intramuscular vitamin B12 supplementation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962879.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


59. Viret F, Ychou M, Baey C, Bennouna J, Adenis A, Peiffert D, Mornex F, Celier P, Montoto-Grillot C, Ducreux M: A phase II study of radiation and docetaxel and cisplatin in the treatment of locally advanced pancreatic carcinoma. FNCLCC-ACCORD 09 /0201 trial. J Clin Oncol; 2009 May 20;27(15_suppl):4625

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of radiation and docetaxel and cisplatin in the treatment of locally advanced pancreatic carcinoma. FNCLCC-ACCORD 09 /0201 trial.
  • : 4625 Background: Locally advanced pancreatic carcinoma remains a challenging tumor with no clear standard of care in terms of radio-chemotherapy.
  • The purpose of this phase II trial was to determine the efficacy and the toxicity of radiotherapy and docetaxel and cisplatin in histologically proven adenocarcinoma of the pancreas.
  • RESULTS: 51 pts (20 women and 31 men, with median age of 62 years) with disease considered to be unresectable but confined to pancreas area and celiac nodes were included between 06/10/2003 and 15/02/2008.
  • 6 pts underwent secondary pancreatic resection (4 compete resection and 1 pt with histological complete remission).
  • CONCLUSIONS: The association docetaxel+cisplatin+radiotherapy has limited effect in patients with locally advanced pancreatic carcinoma but major objective responses have been observed allowing secondary resections.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964209.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Smith CD, Maines LW, Zhuang Y, Green CL, Keller SN, Beljanski V, Knaak C, Wang W: Preclinical development of orally available sphingosine kinase inhibitors. J Clin Oncol; 2009 May 20;27(15_suppl):e14615

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Antitumor activity was assessed in an allogeneic model utilizing murine JC mammary adenocarcinoma cells growing in Balb/c mice, and a xenograft model of human Bxpc pancreatic adenocarcinoma cells growing in scid-mice.
  • CONCLUSIONS: These newly developed SK inhibitors provide orally-available drug candidates for the treatment of pancreatic cancer and other diseases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964127.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. Tedesco KL, Berlin J, Rothenberg M, Choy H, Wyman K, Scott Pearson A, Daniel Beauchamp R, Merchant N, Lockhart AC, Shyr Y, Caillouette C, Chakravarthy B: A phase I study of concurrent 9-nitro-20(s)-camptothecin (9NC/Orathecin) and radiation therapy in the treatment of locally advanced adenocarcinoma of the pancreas. Radiother Oncol; 2005 Jul;76(1):54-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I study of concurrent 9-nitro-20(s)-camptothecin (9NC/Orathecin) and radiation therapy in the treatment of locally advanced adenocarcinoma of the pancreas.
  • We conducted a phase I study to assess the toxicity and determine the maximum tolerated dose of 9NC when combined with radiation in patients with locally advanced adenocarcinoma of the pancreas.
  • PATIENTS AND METHODS: Eleven patients with locally advanced adenocarcinoma of the pancreas received 9NC, orally during radiation.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Camptothecin / analogs & derivatives. Pancreatic Neoplasms / radiotherapy. Radiation-Sensitizing Agents / administration & dosage

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15921772.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / M01 RR 00095; United States / NCI NIH HHS / CA / P30 CA68485
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Radiation-Sensitizing Agents; H19C446XXB / rubitecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


62. Ueno H, Okusaka T, Furuse J, Ishii H, Saijo N, Saito Y, Sawada J, Sakamoto H, Yoshida T, Sato Y: Use of a genome-wide association study to detect candidate polymorphisms associated with overall survival in stage IV pancreatic adenocarcinoma patients receiving gemcitabine monotherapy. J Clin Oncol; 2009 May 20;27(15_suppl):4611

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of a genome-wide association study to detect candidate polymorphisms associated with overall survival in stage IV pancreatic adenocarcinoma patients receiving gemcitabine monotherapy.
  • We performed a genome-wide association study (GWAS) in Japanese patients with stage IV pancreatic adenocarcinoma receiving gemcitabine (Gem) monotherapy.
  • METHODS: Metastatic pancreatic ductal adenocarcinoma patients who had previously received neither radiation nor chemotherapy were eligible in this study.
  • CONCLUSIONS: GWAS is a powerful tool to search for new prognostic biomarkers for patients with stage IV pancreatic adenocarcinoma receiving Gem monotherapy and may reveal as yet unexplored molecular pathways which correlate with drug response.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964191.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Suda K, Nobukawa B, Yamasaki S, Abe K, Matsukuma S, Suzuki F: Invasive ductal adenocarcinoma of the pancreas may originate from the larger pancreatic duct: a study of 13 tumors less than 2 cm in diameter. J Hepatobiliary Pancreat Surg; 2007;14(3):283-8
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Invasive ductal adenocarcinoma of the pancreas may originate from the larger pancreatic duct: a study of 13 tumors less than 2 cm in diameter.
  • BACKGROUND/PURPOSE: We aimed to elucidate the origin/primary site of invasive ductal adenocarcinoma of the pancreas, based on the distribution of intraductal carcinoma components.
  • METHODS: Thirteen specimens from patients with invasive ductal adenocarcinoma (microscopically, less than 2 cm in diameter) of the pancreas were studied histopathologically.
  • Variants of invasive ductal adenocarcinoma and intraductal papillary-mucinous carcinoma were excluded.
  • RESULTS: Intraductal carcinoma components of invasive ductal adenocarcinoma were found in 12 of the specimens 13 (92%), and were observed within the tumor mass and/or on its boundary, or outside the tumor mass.
  • The distribution of the intraductal components in the 12 specimens was as follows: in 9 (75%), they were in both the main pancreatic duct and large branch ducts; and in 3, they were in the smaller branch ducts only.
  • CONCLUSIONS: Invasive ductal adenocarcinomas of the pancreas may originate most frequently from the main pancreatic duct or larger branch ducts, while the smaller ducts are less often the site of cancer origin.
  • [MeSH-major] Carcinoma, Pancreatic Ductal / pathology. Pancreatic Ducts / pathology. Pancreatic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17520204.001).
  • [ISSN] 0944-1166
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Japan
  •  go-up   go-down


64. Ouaissi M, Hubert C, Verhelst R, Astarci P, Sempoux C, Jouret-Mourin A, Loundou A, Gigot JF, Multidisciplary HPB Group of Center of Cancer: Vascular reconstruction during pancreatoduodenectomy for ductal adenocarcinoma of the pancreas improves resectability but does not achieve cure. World J Surg; 2010 Nov;34(11):2648-61
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vascular reconstruction during pancreatoduodenectomy for ductal adenocarcinoma of the pancreas improves resectability but does not achieve cure.
  • OBJECTIVE: Combined vascular and pancreatic resection improves long-term survival of patients suffering from ductal adenocarcinoma of the pancreatic head.
  • This study was designed to compare the results of surgical resection in patients with pancreatic cancer with or without vascular resection.
  • R1 resection was significantly more frequent in groups B (42%) and C (50%) compared with group A (13%; p = 0.0002), but there were more advanced tumors in these groups, as demonstrated by a lower Karnowsky index, higher Ca 19-9 plasmatic level, greater tumor size, more advanced stage in the AJCC classification, and more tumor location in the uncinate process of the pancreas.
  • CONCLUSIONS: Vascular resection combined to pancreatoduodenectomy for pancreatic cancer increases local resectability without increasing mortality and morbidity rates but does not improve patients' disease cure rate.
  • [MeSH-major] Carcinoma, Pancreatic Ductal / surgery. Pancreatic Neoplasms / surgery. Pancreaticoduodenectomy / methods. Vascular Surgical Procedures

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg. 2001 Aug;182(2):120-9 [11574081.001]
  • [Cites] Br J Surg. 2006 Oct;93(10):1232-7 [16804874.001]
  • [Cites] J Clin Oncol. 2002 Aug 1;20(15):3270-5 [12149301.001]
  • [Cites] JAMA. 2007 Jan 17;297(3):267-77 [17227978.001]
  • [Cites] Pancreas. 2004 Apr;28(3):289-92 [15084973.001]
  • [Cites] J Am Coll Surg. 2005 Sep;201(3):359-65 [16125068.001]
  • [Cites] J Clin Oncol. 2007 Jun 20;25(18):2607-15 [17577041.001]
  • [Cites] Am J Surg. 2004 Jun;187(6):736-40 [15191867.001]
  • [Cites] Surgery. 1995 Jan;117(1):50-5 [7809836.001]
  • [Cites] J Gastrointest Surg. 2004 Dec;8(8):935-49; discussion 949-50 [15585381.001]
  • [Cites] Surgery. 2001 Feb;129(2):158-63 [11174708.001]
  • [Cites] J Gastrointest Surg. 2003 Dec;7(8):1089-95 [14675720.001]
  • [Cites] Surgery. 2009 Nov;146(5):869-81 [19744432.001]
  • [Cites] Pancreas. 2004 Apr;28(3):231-4 [15084962.001]
  • [Cites] Ann Surg. 1977 Jul;186(1):42-50 [195543.001]
  • [Cites] Eur J Surg Oncol. 2009 Sep;35(9):1006-10 [19423267.001]
  • [Cites] Pancreas. 2004 Apr;28(3):219-30 [15084961.001]
  • [Cites] CA Cancer J Clin. 2002 Jan-Feb;52(1):23-47 [11814064.001]
  • [Cites] Am J Gastroenterol. 1991 Aug;86(8):1027-32 [1858739.001]
  • [Cites] Langenbecks Arch Surg. 2003 Apr;388(2):101-6 [12684805.001]
  • [Cites] Surg Today. 2002;32(7):598-601 [12111516.001]
  • [Cites] Ann Surg. 1995 Jun;221(6):721-31; discussion 731-3 [7794076.001]
  • [Cites] J Am Coll Surg. 2008 Mar;206(3):451-7 [18308215.001]
  • [Cites] Ann Surg Oncol. 2008 Jun;15(6):1651-60 [18351300.001]
  • [Cites] Arch Surg. 2009 Feb;144(2):154-9 [19221327.001]
  • [Cites] Ann Surg Oncol. 2008 May;15(5):1399-406 [18320285.001]
  • [Cites] Ann Surg. 1990 Apr;211(4):447-58 [2322039.001]
  • [Cites] Pancreas. 1998 Apr;16(3):255-64 [9548664.001]
  • [Cites] World J Surg. 2006 Jun;30(6):976-82; discussion 983-4 [16736324.001]
  • [Cites] J Clin Oncol. 2008 Jul 20;26(21):3496-502 [18640930.001]
  • [Cites] Jpn J Clin Oncol. 2004 May;34(5):238-44 [15231857.001]
  • [Cites] Br J Surg. 2004 May;91(5):586-94 [15122610.001]
  • [Cites] J Gastrointest Surg. 2000 Nov-Dec;4(6):567-79 [11307091.001]
  • [Cites] J Clin Oncol. 2005 Jul 10;23(20):4538-44 [16002845.001]
  • [Cites] World J Surg. 2007 Jan;31(1):147-54 [17171496.001]
  • [Cites] J Clin Oncol. 2008 Jul 20;26(21):3487-95 [18640929.001]
  • [Cites] Br J Surg. 1995 Jan;82(1):111-5 [7881926.001]
  • [Cites] Cancer. 2002 May 1;94(9):2511-6 [12015777.001]
  • [Cites] Br J Surg. 1994 Nov;81(11):1642-6 [7827892.001]
  • [Cites] World J Surg. 2006 Aug;30(8):1526-35 [16855797.001]
  • [Cites] Br J Surg. 2006 Jun;93(6):662-73 [16703621.001]
  • [Cites] Am J Surg. 2003 Aug;186(2):149-53 [12885608.001]
  • [Cites] Ann Surg. 1997 Sep;226(3):248-57; discussion 257-60 [9339931.001]
  • [Cites] World J Surg. 2004 Jun;28(6):602-8 [15366753.001]
  • [Cites] J Gastrointest Surg. 2008 Jan;12(1):91-100 [17786524.001]
  • [Cites] Eur J Surg Oncol. 2009 Dec;35(12):1306-11 [19576722.001]
  • [Cites] Ann Surg Oncol. 2009 Apr;16(4):836-47 [19194760.001]
  • [Cites] Ann Surg. 2004 Aug;240(2):205-13 [15273542.001]
  • [Cites] J Am Coll Surg. 2008 May;206(5):833-46; discussion 846-8 [18471707.001]
  • [Cites] CA Cancer J Clin. 1997 Jan-Feb;47(1):5-27 [8996076.001]
  • [Cites] Surgery. 2007 Jul;142(1):20-5 [17629996.001]
  • [Cites] Pancreas. 2009 Apr;38(3):282-8 [19142173.001]
  • [Cites] Ann Surg. 2001 Dec;234(6):758-68 [11729382.001]
  • [Cites] West J Med. 1991 Oct;155(4):384-7 [1771876.001]
  • [Cites] Anesthesiology. 1978 Oct;49(4):239-43 [697077.001]
  • [Cites] Surgery. 2005 Jul;138(1):8-13 [16003309.001]
  • [Cites] N Engl J Med. 2004 Mar 18;350(12):1200-10 [15028824.001]
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2403-13 [9196156.001]
  • [Cites] Br J Surg. 1994 Aug;81(8):1190-3 [7953357.001]
  • [Cites] Ann Surg. 2008 Feb;247(2):300-9 [18216537.001]
  • [Cites] Ann Surg. 2007 Jul;246(1):52-60 [17592291.001]
  • [Cites] World J Surg. 2001 Aug;25(8):1002-5 [11571964.001]
  • [Cites] Virchows Arch. 1998 Sep;433(3):237-42 [9769127.001]
  • [Cites] HPB (Oxford). 2006;8(6):465-73 [18333103.001]
  • (PMID = 20607257.001).
  • [ISSN] 1432-2323
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Investigator] Annet L; Van Beers BE; Deprez P; Borbath I; Humblet Y; Van Den Eyden M; Scalliet P
  •  go-up   go-down


65. Golcher H, Brunner T, Grabenbauer G, Merkel S, Papadopoulos T, Hohenberger W, Meyer T: Preoperative chemoradiation in adenocarcinoma of the pancreas. A single centre experience advocating a new treatment strategy. Eur J Surg Oncol; 2008 Jul;34(7):756-64
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative chemoradiation in adenocarcinoma of the pancreas. A single centre experience advocating a new treatment strategy.
  • AIMS: To evaluate a single centre's experience with pancreatic carcinoma focused on preoperative chemoradiation therapy (CRT) for treatment of locally advanced pancreatic carcinoma.
  • The aim of the present analysis was to evaluate the median overall survival time (OS) after preoperative CRT and to compare it with OS after primary resection of pancreatic carcinoma.
  • In conclusion a new treatment strategy was developed using multimodality treatment for pancreatic carcinoma deemed to be resectable by CT-scan.
  • PATIENTS AND METHODS: Between 1995 and 2003, 302 patients with ductal adenocarcinoma of the pancreatic head and body were recorded prospectively and OS was analysed with regard to therapy.
  • CONCLUSION: CRT pretreatment was effective in locally advanced pancreatic carcinoma and resulted in resection of tumours otherwise staged as non-resectable.
  • This experience led to a randomized trial for patients who by CT are staged to have resectable cancer of the pancreatic head with the intent to increase curative resectability and survival by neoadjuvant CRT (ISRCTN78805636/NCT00335543).
  • [MeSH-major] Carcinoma, Pancreatic Ductal / drug therapy. Carcinoma, Pancreatic Ductal / radiotherapy. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18191528.001).
  • [ISSN] 1532-2157
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00335543; ISRCTN/ ISRCTN78805636
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


66. Kawakami H, Kuwatani M, Fujiya Y, Uebayashi M, Konishi K, Makiyama H, Hashino S, Kubota K, Itoh T, Asaka M: [A case of granulocyte-colony stimulating factor producing ductal adenocarcinoma of the pancreas]. Nihon Shokakibyo Gakkai Zasshi; 2007 Feb;104(2):233-8
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of granulocyte-colony stimulating factor producing ductal adenocarcinoma of the pancreas].
  • We report a case of pancreatic ductal adenocarcinoma producing granulocyte-colony stimulating factor (G-CSF).
  • An abdominal CT scan revealed masses in the pancreatic body to the tail, and both lobes of the liver.
  • A biopsy specimen of the hepatic tumor demonstrated metastatic poorly differentiated adenocarcinoma.
  • The diagnosis of autopsy was pancreatic ductal adenocarcinoma.
  • The final diagnosis was G-CSF-producing pancreatic carcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Carcinoma, Pancreatic Ductal / metabolism. Granulocyte Colony-Stimulating Factor / biosynthesis. Pancreatic Neoplasms / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17283419.001).
  • [ISSN] 0446-6586
  • [Journal-full-title] Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology
  • [ISO-abbreviation] Nihon Shokakibyo Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Interleukin-6; 143011-72-7 / Granulocyte Colony-Stimulating Factor
  •  go-up   go-down


67. Schleicher C, Poremba C, Wolters H, Schäfer KL, Senninger N, Colombo-Benkmann M: Gain of chromosome 8q: a potential prognostic marker in resectable adenocarcinoma of the pancreas? Ann Surg Oncol; 2007 Apr;14(4):1327-35
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gain of chromosome 8q: a potential prognostic marker in resectable adenocarcinoma of the pancreas?
  • BACKGROUND: The objective of this study was to identify genomic alterations in resectable pancreatic cancer (PCA).
  • [MeSH-major] Adenocarcinoma / genetics. Biomarkers, Tumor / genetics. Chromosomes, Human, Pair 8 / genetics. Gene Amplification. Pancreatic Neoplasms / genetics
  • [MeSH-minor] Adenocarcinoma, Mucinous / genetics. Adult. Aged. Aged, 80 and over. Carcinoma, Pancreatic Ductal / genetics. Chromosome Aberrations. DNA / metabolism. Female. Humans. Image Processing, Computer-Assisted. Male. Middle Aged. Nucleic Acid Hybridization. Prognosis. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17235717.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 9007-49-2 / DNA
  •  go-up   go-down


68. Lévy P: [Adenocarcinoma of the pancreas: are CA 19-9 assays useful?]. Presse Med; 2008 Jan;37(1 Pt 2):88-94
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adenocarcinoma of the pancreas: are CA 19-9 assays useful?].
  • [Transliterated title] Adénocarcinome du pancréas: le dosage du CA 19-9 a-t-il un intérêt ?
  • The CA 19-9 assay is not a sensitive examination that is useful for the diagnosis of a resectable pancreatic tumor.
  • [MeSH-major] Adenocarcinoma / blood. Biomarkers, Tumor / blood. CA-19-9 Antigen / blood. Pancreatic Neoplasms / blood

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17980545.001).
  • [ISSN] 0755-4982
  • [Journal-full-title] Presse medicale (Paris, France : 1983)
  • [ISO-abbreviation] Presse Med
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-19-9 Antigen
  • [Number-of-references] 73
  •  go-up   go-down


69. Jarry J, Belleannee G, Rault A, Sa Cunha A, Collet D: Can an intraductal papillary mucinous tumor be a potential indicator of concurrent adenocarcinoma of the pancreas? JOP; 2010;11(1):55-7
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Can an intraductal papillary mucinous tumor be a potential indicator of concurrent adenocarcinoma of the pancreas?
  • CONTEXT: Despite the recent progress of diagnostic and therapeutic modalities, survival rates of pancreatic adenocarcinoma remain poor, mainly due to late diagnosis.
  • CASE REPORT: We report the case of a 56-year-old man who was diagnosed with a symptomatic intraductal papillary mucinous tumor of the pancreas located in the uncus.
  • This tumor was associated with a concurrent stenosis of the isthmic pancreatic duct which resulted in a distal dilation.
  • During the procedure, a concomitant adenocarcinoma was diagnosed 2 cm from the primary intraductal papillary mucinous tumor, causing the isthmic stenosis.
  • A second resection was then performed to the left of the pancreatic isthmus, and adjuvant chemotherapy was performed.
  • CONCLUSION: We discuss the possibility that intraductal papillary mucinous tumors may be a "red flag" enabling earlier diagnosis of a concurrent pancreatic adenocarcinoma arising in another area of the pancreas.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma, Mucinous / diagnosis. Carcinoma, Pancreatic Ductal / diagnosis. Carcinoma, Papillary / diagnosis. Neoplasms, Multiple Primary / diagnosis. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Early Detection of Cancer. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20065554.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


70. Ohike N, Sato M, Kawahara M, Ohyama S, Morohoshi T: Ductal adenocarcinoma of the pancreas with psammomatous calcification. Report of a case. JOP; 2008;9(3):335-8
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ductal adenocarcinoma of the pancreas with psammomatous calcification. Report of a case.
  • CONTEXT: Calcification is extremely rare in pancreatic ductal adenocarcinomas, but we may sometimes encounter focal dystrophic calcification.
  • CASE REPORT: We herein report the case of an 83-year-old female with pancreatic ductal adenocarcinoma associated with diffuse psammomatous calcification.
  • CONCLUSIONS: The possibility of pancreatic ductal adenocarcinoma should therefore be considered for a localized calcified lesion in the pancreas.
  • Studies to elucidate the prognostic significance of psammoma bodies in pancreatic ductal adenocarcinomas are therefore recommended.
  • [MeSH-major] Calcinosis / complications. Carcinoma, Pancreatic Ductal / complications. Pancreatic Neoplasms / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18469450.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


71. Chan E, Mulkerin D, Rothenberg M, Holen KD, Lockhart AC, Thomas J, Berlin J: A phase I trial of CEP-701 + gemcitabine in patients with advanced adenocarcinoma of the pancreas. Invest New Drugs; 2008 Jun;26(3):241-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I trial of CEP-701 + gemcitabine in patients with advanced adenocarcinoma of the pancreas.
  • INTRODUCTION: Current standard therapy for advanced pancreas cancer includes the use of gemcitabine or a gemcitabine-based chemotherapy regimen.
  • Although too few patients were enrolled to fully evaluate efficacy, there was not significant evidence for pursuing this combination further in pancreas cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Pancreatic Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18217204.001).
  • [ISSN] 0167-6997
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carbazoles; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; DO989GC5D1 / lestaurtinib
  •  go-up   go-down


72. Gamblin TC, Egorin MJ, Zuhowski EG, Lagattuta TF, Herscher LL, Russo A, Libutti SK, Alexander HR, Dedrick RL, Bartlett DL: Intraperitoneal gemcitabine pharmacokinetics: a pilot and pharmacokinetic study in patients with advanced adenocarcinoma of the pancreas. Cancer Chemother Pharmacol; 2008 Sep;62(4):647-53
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraperitoneal gemcitabine pharmacokinetics: a pilot and pharmacokinetic study in patients with advanced adenocarcinoma of the pancreas.
  • BACKGROUND: The pyrimidine analogue gemcitabine (2', 2'-difluorodeoxycitidine, dFdC) is active against pancreatic cancer, and its high clearance (CL(tb)) and low incidence of local toxicity make it an excellent candidate for evaluation as intraperitoneal (IP) therapy.
  • METHODS: As part of a study involving multi-modality therapy for advanced pancreatic adenocarcinoma, patients were treated with four 6-h IP dwells of dFdC (50 mg/m(2) in 2 l) over a 24-h period.
  • [MeSH-major] Adenocarcinoma / metabolism. Antimetabolites, Antineoplastic / pharmacokinetics. Deoxycytidine / analogs & derivatives. Pancreatic Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18040687.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / K12 HD049109; United States / NCI NIH HHS / CA / P30CA 47904
  • [Publication-type] Clinical Trial; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Dialysis Solutions; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


73. Shamamian P, Goldberg JD, Ye XY, Stewart JD, White PJ, Gilvarg C: Evaluation of pro-carboxypeptidase A and carboxypeptidase A as serologic markers for adenocarcinoma of the pancreas. HPB (Oxford); 2006;8(6):451-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of pro-carboxypeptidase A and carboxypeptidase A as serologic markers for adenocarcinoma of the pancreas.
  • BACKGROUND: A serological marker for pancreatic cancer may allow for early detection and potentially more effective treatments.
  • Pro-carboxypeptidase A (pro-CPA) is produced exclusively in the pancreas and converted to its active form, CPA, in the intestinal lumen.
  • We hypothesized that alterations in serum pro-CPA and/or CPA may be useful as a diagnostic test for pancreatic cancer.
  • PATIENTS AND METHODS: Serum samples obtained from 34 patients with pancreatic adenocarcinoma prior to surgical intervention and 64 control patients were assayed for pro-CPA and CPA.
  • A variety of statistical methods was used to evaluate the utility of these measurements individually and in combination to classify the samples with respect to the presence or absence of pancreatic adenocarcinoma.
  • All pancreatic cancer patients had ln(CPA) levels within or below the normal range defined as two standard deviations from the control group mean (-2.714+/-0.413).
  • Pancreatic cancer patients with ln pro-CPA values within the control range had low ln CPA, advanced stage and/or evidence of pancreatic insufficiency.
  • While each of these individual values (ln pro-CPA or ln CPA) does not adequately separate all control from cancer patients, a bivariate classification rule is presented that uses both ln pro-CPA and ln CPA simultaneously to predict the presence of pancreatic cancer with a sensitivity of 91% and a specificity of 95%.
  • CONCLUSIONS: The data presented suggest that abnormalities in serum pro-CPA and CPA levels are associated with the presence of pancreatic cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Oncol Clin N Am. 1998 Jan;7(1):103-24 [9443989.001]
  • [Cites] Ann Surg Oncol. 1997 Dec;4(8):639-43 [9416411.001]
  • [Cites] Clin Chim Acta. 1999 Mar;281(1-2):19-28 [10217623.001]
  • [Cites] J Gastrointest Surg. 1999 Sep-Oct;3(5):506-11 [10482707.001]
  • [Cites] Clin Chim Acta. 2000 Feb 25;292(1-2):107-15 [10686280.001]
  • [Cites] J Gastrointest Surg. 2000 Nov-Dec;4(6):567-79 [11307091.001]
  • [Cites] CA Cancer J Clin. 2002 Jan-Feb;52(1):23-47 [11814064.001]
  • [Cites] Surg Oncol Clin N Am. 2002 Jan;11(1):207-29, x [11930875.001]
  • [Cites] Clin Chem. 1989 Feb;35(2):251-5 [2464445.001]
  • [Cites] Anal Biochem. 1987 Feb 15;161(1):219-25 [3578784.001]
  • [Cites] Clin Chim Acta. 1983 Nov 30;135(1):65-71 [6197212.001]
  • [Cites] Anal Biochem. 1982 Sep 15;125(2):420-6 [7181100.001]
  • [Cites] Ann Surg. 1995 Jun;221(6):721-31; discussion 731-3 [7794076.001]
  • [Cites] Surg Oncol. 1996 Apr;5(2):49-63 [8853239.001]
  • [Cites] J Gastrointest Surg. 1997 Mar-Apr;1(2):106-12 [9834336.001]
  • (PMID = 18333101.001).
  • [ISSN] 1365-182X
  • [Journal-full-title] HPB : the official journal of the International Hepato Pancreato Biliary Association
  • [ISO-abbreviation] HPB (Oxford)
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016087
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2020764
  •  go-up   go-down


74. Stefanidis D, Grove KD, Schwesinger WH, Thomas CR Jr: The current role of staging laparoscopy for adenocarcinoma of the pancreas: a review. Ann Oncol; 2006 Feb;17(2):189-99
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The current role of staging laparoscopy for adenocarcinoma of the pancreas: a review.
  • In the absence of metastatic disease patients with localized or locally advanced pancreatic cancer can benefit from surgical resection or chemoradiation.
  • A controversy exists, however, as to whether the procedure should be used routinely or selectively in pancreatic cancer patients with no evidence of metastasis on noninvasive staging.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16236756.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 80
  •  go-up   go-down


75. Park HS, Jang KY, Kim YK, Yu HC, Cho BH, Moon WS: Cystic lesion mimicking intraductal papillary mucinous tumor arising in heterotopic pancreas of the stomach and synchronous intraductal papillary mucinous adenocarcinoma of the pancreas. Int J Surg Pathol; 2008 Jul;16(3):324-8
MedlinePlus Health Information. consumer health - Stomach Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cystic lesion mimicking intraductal papillary mucinous tumor arising in heterotopic pancreas of the stomach and synchronous intraductal papillary mucinous adenocarcinoma of the pancreas.
  • This article presents the study of a 66-year-old man with an asymptomatic pancreatic mass detected incidentally 4 months earlier.
  • A magnetic resonance imaging scan revealed 2 distinct cystic masses in the pancreas and the gastric antrum.
  • Microscopically, the pancreatic lesion showed dilated cysts containing papillary structures lined by mucinous epithelium, which showed a loss of polarity, an increased nucleus-to-cytoplasm ratio, a prominent nucleolus, and high proliferation on immunostaining for Ki-67.
  • The gastric lesion was composed of heterotopic pancreatic tissue surrounding a large dilated cyst that was lined with mucinous epithelium and contained a few intraluminal papillae.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma, Pancreatic Ductal / pathology. Choristoma. Neoplasms, Multiple Primary / pathology. Pancreas. Pancreatic Cyst / pathology. Pancreatic Neoplasms / pathology. Stomach Diseases / pathology
  • [MeSH-minor] Aged. Cell Proliferation. Diagnosis, Differential. Disease-Free Survival. Gastrectomy. Humans. Ki-67 Antigen / metabolism. Magnetic Resonance Imaging. Male. Pancreaticoduodenectomy

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18387995.001).
  • [ISSN] 1066-8969
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ki-67 Antigen
  •  go-up   go-down


76. Cohen SJ, Dobelbower R Jr, Lipsitz S, Catalano PJ, Sischy B, Smith TJ, Haller DG, Eastern Cooperative Oncology Group: A randomized phase III study of radiotherapy alone or with 5-fluorouracil and mitomycin-C in patients with locally advanced adenocarcinoma of the pancreas: Eastern Cooperative Oncology Group study E8282. Int J Radiat Oncol Biol Phys; 2005 Aug 1;62(5):1345-50
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized phase III study of radiotherapy alone or with 5-fluorouracil and mitomycin-C in patients with locally advanced adenocarcinoma of the pancreas: Eastern Cooperative Oncology Group study E8282.
  • PURPOSE: The median survival time of patients with locally advanced adenocarcinoma of the pancreas is 8-10 months.
  • CONCLUSION: The addition of 5-FU and MMC to radiotherapy increased toxicity without improving DFS or OS in patients with locally advanced pancreatic cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16029791.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA07190; United States / NCI NIH HHS / CA / CA11083; United States / NCI NIH HHS / CA / CA15488; United States / NCI NIH HHS / CA / CA21115; United States / NCI NIH HHS / CA / CA23318; United States / NCI NIH HHS / CA / CA27525; United States / NCI NIH HHS / CA / CA66636
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


77. Lisovsky M, Dresser K, Woda B, Mino-Kenudson M: Immunohistochemistry for cell polarity protein lethal giant larvae 2 differentiates pancreatic intraepithelial neoplasia-3 and ductal adenocarcinoma of the pancreas from lower-grade pancreatic intraepithelial neoplasias. Hum Pathol; 2010 Jun;41(6):902-9
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemistry for cell polarity protein lethal giant larvae 2 differentiates pancreatic intraepithelial neoplasia-3 and ductal adenocarcinoma of the pancreas from lower-grade pancreatic intraepithelial neoplasias.
  • Pancreatic intraepithelial neoplasia is a precursor to ductal adenocarcinoma of the pancreas that shows gastric differentiation.
  • Pancreatic intraepithelial neoplasia-3 has the highest potential to progress to adenocarcinoma, and its distinction from lower-grade pancreatic intraepithelial neoplasias is important for clinical management.
  • However, morphologic grading of pancreatic intraepithelial neoplasia suffers from significant interobserver variability.
  • A product of cell polarity gene lethal giant larvae 2 is a marker of gastric foveolar epithelium expressed in a basolateral fashion, which is lost or mislocalized in gastric epithelial dysplasia and adenocarcinoma.
  • In this study, we investigated a role of lethal giant larvae 2 expression in differentiating low-grade pancreatic intraepithelial neoplasias, that is, pancreatic intraepithelial neoplasia-1 and pancreatic intraepithelial neoplasia-2, from pancreatic intraepithelial neoplasia-3 and pancreatic ductal adenocarcinoma.
  • The immunohistochemical patterns of lethal giant larvae 2 expression were examined in normal pancreatic ducts, 48 pancreatic intraepithelial neoplasia lesions of all histologic grades, and 91 adenocarcinomas on a tissue microarray or conventional sections.
  • Whereas normal duct epithelia did not exhibit lethal giant larvae immunoreactivity, all but one lesion of low-grade pancreatic intraepithelial neoplasia showed basolateral lethal giant larvae staining.
  • Conversely, all lesions of pancreatic intraepithelial neoplasia-3 and adenocarcinoma showed loss of lethal giant larvae 2 staining and/or its cytoplasmic localization.
  • In conclusion, our results show that low-grade pancreatic intraepithelial neoplasias express lethal giant larvae 2 in a basolateral fashion recapitulating expression in normal gastric epithelium.
  • Loss or abnormal lethal giant larvae 2 expression is seen in pancreatic intraepithelial neoplasia-3 and adenocarcinoma and might be useful in separating them from lower-grade pancreatic intraepithelial neoplasias.
  • [MeSH-major] Carcinoma in Situ / diagnosis. Carcinoma, Pancreatic Ductal / diagnosis. Cytoskeletal Proteins / biosynthesis. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Biomarkers, Tumor / biosynthesis. Cell Polarity. Diagnosis, Differential. Gastric Mucosa / metabolism. Humans. Immunohistochemistry. Pancreas / metabolism. Pancreas / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20233622.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cytoskeletal Proteins; 0 / Hugl-2 protein, human
  •  go-up   go-down


78. Ben-Josef E, Griffith K, Francis IR, Khan G, Lawrence TS, Abrams R, Leslie W, Zalupski M: Phase I radiation dose-escalation trial of intensity-modulated radiotherapy (IMRT) with concurrent fixed dose-rate gemcitabine (FDR-G) for unresectable pancreatic cancer. J Clin Oncol; 2009 May 20;27(15_suppl):4602

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I radiation dose-escalation trial of intensity-modulated radiotherapy (IMRT) with concurrent fixed dose-rate gemcitabine (FDR-G) for unresectable pancreatic cancer.
  • : 4602 Background: Current treatments of non-metastatic, unresectable pancreatic cancer result in poor survival and nearly uniform local persistence of disease.
  • METHODS: Eligibility included tissue diagnosis of adenocarcinoma, unresectable by radiological criteria, Zubrod performance of 0-2, ANC of ≥ 1500/mm3, platelets ≥ 100,000/mm3, creatinine < 2 mg/dl, bilirubin < 3 mg/dl, ALT and AST ≤ 2.5 x ULN, and informed consent.
  • GTV was defined on pancreas protocol CT in the treatment position.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964152.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


79. Badía Bartolomé C, Díaz Formoso FJ, Rodríguez Falcón R, Marchena Gómez J: [Groove pancreatitis and its differential diagnosis with pancreatic adenocarcinoma]. Gastroenterol Hepatol; 2009 Jan;32(1):22-8
MedlinePlus Health Information. consumer health - Pancreatitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Groove pancreatitis and its differential diagnosis with pancreatic adenocarcinoma].
  • [Transliterated title] Pancreatitis del surco y su diagnóstico diferencial con el adenocarcinoma de páncreas.
  • We analyzed the clinical, radiographic and histologic characteristics, as well as the difficulties that arose in the differential diagnosis between groove pancreatitis (a benign entity consisting of a segmental form of chronic pancreatitis occurring as a sheet-like scar in the area of pancreatoduodenal groove) and adenocarcinoma of the pancreas.
  • To this end, four cases with abnormalities in the groove area were retrospectively reviewed, three with groove pancreatitis, and one with adenocarcinoma of the pancreas.
  • The important role of imaging techniques is highlighted, with emphasis on magnetic resonance imaging of the pancreas and magnetic resonance cholangiography, which reveal certain differentiating characteristics between these two entities.
  • [MeSH-major] Adenocarcinoma / diagnosis. Duodenitis / diagnosis. Pancreatic Neoplasms / diagnosis. Pancreatitis / diagnosis
  • [MeSH-minor] Adult. Aged. Biopsy, Fine-Needle. Cholangiopancreatography, Endoscopic Retrograde. Cholangiopancreatography, Magnetic Resonance. Cholelithiasis / complications. Cholelithiasis / diagnosis. Chronic Disease. Diagnosis, Differential. Duodenum / pathology. Fatal Outcome. Humans. Intestinal Mucosa / pathology. Magnetic Resonance Imaging. Male. Middle Aged. Pancreaticoduodenectomy. Pancreatitis, Alcoholic / complications. Retrospective Studies

  • Genetic Alliance. consumer health - Pancreatitis.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Gastroenterol Hepatol. 2009 Nov;32(9):662-3 [19525034.001]
  • (PMID = 19174095.001).
  • [ISSN] 0210-5705
  • [Journal-full-title] Gastroenterología y hepatología
  • [ISO-abbreviation] Gastroenterol Hepatol
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


80. Uronis HE, Bullock K, Blobe G, Hsu S, Morse M, Nixon A, Haley S, O'Neill M, Hurwitz H, Bendell J: A phase I study of gemcitabine plus dasatinib (GD) or gemcitabine plus dasatinib plus cetuximab (GDC) in refractory solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):e15506

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: 25 pts have been enrolled, including 21 with pancreatic adenocarcinoma, 3 of whom had received prior G. 21 pts were evaluable for toxicity and 18 for efficacy.
  • To address these toxicities, once daily dosing of D will be explored, followed by an expanded cohort of G + daily D vs G + bid D in pts with treatment-naïve pancreatic cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962236.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


81. Witkiewicz AK, Kennedy EP, Kennyon L, Yeo CJ, Hruban RH: Synchronous autoimmune pancreatitis and infiltrating pancreatic ductal adenocarcinoma: case report and review of the literature. Hum Pathol; 2008 Oct;39(10):1548-51
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous autoimmune pancreatitis and infiltrating pancreatic ductal adenocarcinoma: case report and review of the literature.
  • Histologic evaluation of the specimen revealed synchronous autoimmune pancreatitis (lymphoplasmacytic sclerosing pancreatitis) and infiltrating ductal adenocarcinoma of the pancreas.
  • The mixed inflammatory infiltrate centered on the pancreatic ducts was associated with acinar loss, parenchymal fibrosis, and obliterative venulitis.
  • Although not appreciated grossly, pancreatic intraepithelial neoplasia-3 and a neurotropic infiltrating poorly differentiated adenocarcinoma of the pancreas were also present.
  • [MeSH-major] Autoimmune Diseases / pathology. Carcinoma in Situ / pathology. Carcinoma, Pancreatic Ductal / pathology. Pancreatic Neoplasms / pathology. Pancreatitis / pathology
  • [MeSH-minor] Aged, 80 and over. Humans. Immunoglobulin G / metabolism. Male. Pancreatic Ducts / metabolism. Pancreatic Ducts / pathology. Pancreaticoduodenectomy. Plasma Cells / metabolism. Plasma Cells / pathology. Treatment Outcome


82. Naugler C, Xu Z: Pancreatic adenocarcinoma metastatic to the pineal gland. J Clin Neurosci; 2008 Nov;15(11):1284-6
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic adenocarcinoma metastatic to the pineal gland.
  • Here we present the case of a 66-year-old female with autosomal dominant polycystic kidney and liver disease who was found at autopsy to have an unrecognized infiltrating ductal adenocarcinoma of the pancreas with metastases to the liver, lungs and pineal gland.
  • As far as we are aware, this is the first report of a metastasis of infiltrating ductal adenocarcinoma of the pancreas to the pineal gland.
  • [MeSH-major] Adenocarcinoma / pathology. Brain Neoplasms / secondary. Pancreatic Neoplasms / pathology. Pineal Gland. Pinealoma / secondary

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18829324.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


83. Collins JM, Silva AC, Hayman LA: Arterial anatomy of the pancreas. Part 3: segmented computed tomography-angiography mapping of perineural invasion. J Comput Assist Tomogr; 2010 Nov-Dec;34(6):961-5
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Arterial anatomy of the pancreas. Part 3: segmented computed tomography-angiography mapping of perineural invasion.
  • This is the third in a series of medical graphics articles featuring the arterial anatomy of the pancreas as depicted on segmented computed tomography-angiography.
  • These segmented computed tomography-angiography displays serve as a road map of the routes of tumor spread by ductal adenocarcinoma of the pancreas because perineural tumor invasion parallels the pancreatic arteries.
  • [MeSH-major] Arteries / anatomy & histology. Neoplasm Invasiveness / radiography. Pancreas / blood supply. Pancreas / radiography. Pancreatic Neoplasms / blood supply. Pancreatic Neoplasms / radiography. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21084917.001).
  • [ISSN] 1532-3145
  • [Journal-full-title] Journal of computer assisted tomography
  • [ISO-abbreviation] J Comput Assist Tomogr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


84. Hruban RH, Takaori K, Canto M, Fishman EK, Campbell K, Brune K, Kern SE, Goggins M: Clinical importance of precursor lesions in the pancreas. J Hepatobiliary Pancreat Surg; 2007;14(3):255-63
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical importance of precursor lesions in the pancreas.
  • Three distinct noninvasive precursor lesions to invasive ductal adenocarcinoma of the pancreas have been described.
  • These include the mucinous cystic neoplasm, intraductal papillary mucinous neoplasm, and pancreatic intraepithelial neoplasia.
  • [MeSH-major] Pancreas / pathology. Pancreatic Neoplasms / pathology. Precancerous Conditions / pathology
  • [MeSH-minor] Carcinoma, Pancreatic Ductal / pathology. Disease Progression. Humans

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17520200.001).
  • [ISSN] 0944-1166
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA62924
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Japan
  • [Number-of-references] 97
  •  go-up   go-down


85. Collins JM, Silva AC, Hayman LA: Arterial anatomy of the pancreas: part 1. Coronal. J Comput Assist Tomogr; 2010 Jul;34(4):633-6
MedlinePlus Health Information. consumer health - CT Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Arterial anatomy of the pancreas: part 1. Coronal.
  • This is the first in a series of 3 medical graphics articles featuring the arterial anatomy of the pancreas as depicted on computed tomography images.
  • This arterial anatomy is important in clinical practice because it represents a road map of the routes of tumor spread by ductal adenocarcinoma of the pancreas.
  • [MeSH-major] Pancreas / blood supply. Pancreas / radiography. Tomography, X-Ray Computed / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20657236.001).
  • [ISSN] 1532-3145
  • [Journal-full-title] Journal of computer assisted tomography
  • [ISO-abbreviation] J Comput Assist Tomogr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


86. Peters K, Klöppel G: [Undifferentiated pancreatic carcinomas. Leap into chaos]. Pathologe; 2005 Feb;26(1):18-21
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Undifferentiated pancreatic carcinomas. Leap into chaos].
  • Undifferentiated pancreatic carcinomas are rare anaplastic variants of ductal adenocarcinoma of the pancreas.
  • An uncommon variant is undifferentiated pancreatic carcinoma with osteoclast-like giant cells.
  • [MeSH-major] Pancreatic Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Carcinoma, Pancreatic Ductal / pathology. Diagnosis, Differential. Humans. Immunohistochemistry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2001 May 20;95(3):194-7 [11307154.001]
  • [Cites] Semin Diagn Pathol. 2000 Feb;17(1):31-42 [10721805.001]
  • [Cites] J Pathol. 1994 Dec;174(4):243-8 [7884585.001]
  • [Cites] Hum Pathol. 1981 Oct;12(10):944-7 [7298052.001]
  • [Cites] Oncol Rep. 2001 Jul-Aug;8(4):745-52 [11410776.001]
  • [Cites] J Pathol. 1998 May;185(1):53-60 [9713360.001]
  • [Cites] Am J Surg Pathol. 1998 Oct;22(10):1247-54 [9777987.001]
  • [Cites] Pathol Res Pract. 1993 Mar;189(2):228-31; discussion 232-4 [8321752.001]
  • [Cites] Eur J Surg Oncol. 1993 Feb;19(1):84-6 [8436245.001]
  • (PMID = 15592673.001).
  • [ISSN] 0172-8113
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


87. Dariusz Szajda S, Waszkiewicz N, Stypułkowska A, Dadan J, Zwierz K: Lysosomal exoglycosidases in serum and urine of patients with pancreatic adenocarcinoma. Folia Histochem Cytobiol; 2010 Sep 30;48(3):351-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lysosomal exoglycosidases in serum and urine of patients with pancreatic adenocarcinoma.
  • The aim of the present paper was evaluation the activity of HEX, GAL, FUC and MAN in serum and urine of patients with pancreatic adenocarcinoma.
  • Serum and urine samples were collected from 15 patients with adenocarcinoma of the pancreas and 15 healthy persons.
  • The activity of lysosomal exoglycosidases was determined by the method of Marciniak et al. adapted to serum and urine of patients with adenocarcinoma of the pancreas.
  • Our results indicate significant decrease in activity of GAL (p=0.037) in serum of patients with pancreatic adenocarcinoma, significant increase in activity of HEX (p<0.001) and FUC (p=0.027) in serum, and HEX (p=0.003) in urine, as well as significant decrease of FUC (p=0.016) and MAN (p=0.029) in urine o patients with adenocarcinoma of the pancreas, in comparison to the control group.
  • Increase in activity of some lysosomal enzymes in serum and urine of pancreatic adenocarcinoma patients, may indicate on destruction of pancreatic tissue by pancreatic adenocarcinoma.
  • Determination of the HEX, GAL, FUC and MAN in serum and urine may be useful in diagnostics of pancreatic adenocarcinoma.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21071338.001).
  • [ISSN] 1897-5631
  • [Journal-full-title] Folia histochemica et cytobiologica
  • [ISO-abbreviation] Folia Histochem. Cytobiol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Glycoconjugates; EC 3.2.1.- / Glycoside Hydrolases; EC 3.2.1.23 / beta-Galactosidase; EC 3.2.1.24 / alpha-Mannosidase; EC 3.2.1.51 / alpha-L-Fucosidase; EC 3.2.1.52 / beta-N-Acetylhexosaminidases
  •  go-up   go-down


88. Nakakura EK, Bergsland EK: Islet cell carcinoma: neuroendocrine tumors of the pancreas and periampullary region. Hematol Oncol Clin North Am; 2007 Jun;21(3):457-73; viii
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Islet cell carcinoma: neuroendocrine tumors of the pancreas and periampullary region.
  • In contrast with patients who have adenocarcinoma of the pancreas, those who have islet cell carcinomas can achieve long-term survival even if their disease is advanced.
  • [MeSH-major] Carcinoma, Islet Cell. Common Bile Duct Neoplasms. Neuroendocrine Tumors. Pancreatic Neoplasms

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17548034.001).
  • [ISSN] 0889-8588
  • [Journal-full-title] Hematology/oncology clinics of North America
  • [ISO-abbreviation] Hematol. Oncol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 57
  •  go-up   go-down


89. Hruban RH, Maitra A, Goggins M: Update on pancreatic intraepithelial neoplasia. Int J Clin Exp Pathol; 2008;1(4):306-16
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Update on pancreatic intraepithelial neoplasia.
  • Pancreatic intraepithelial neoplasia (PanIN) is a histologically well-defined precursor to invasive ductal adenocarcinoma of the pancreas.
  • Molecular studies have helped establish the progression of PanIN to invasive cancer, and recently genetically engineered mouse models have been generated that recapitulate the entire spectrum of lesions from precursor to invasive pancreatic cancer.
  • Some PanIN lesions produce lobulocentric atrophy of the pancreatic parenchyma, and, when multifocal, this lobulocentric atrophy may be detectable using currently available imaging techniques such as endoscopic ultrasound.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Cell. 2005 Sep;8(3):185-95 [16169464.001]
  • [Cites] Cancer Cell. 2005 May;7(5):469-83 [15894267.001]
  • [Cites] Nat Methods. 2004 Nov;1(2):141-7 [15782177.001]
  • [Cites] Am J Surg Pathol. 2003 Dec;27(12):1495-501 [14657708.001]
  • [Cites] Mod Pathol. 2003 Oct;16(10):996-1006 [14559982.001]
  • [Cites] J Natl Cancer Inst. 2003 Apr 16;95(8):622-5 [12697855.001]
  • [Cites] Cancer Biol Ther. 2003 Jan-Feb;2(1):78-83 [12673124.001]
  • [Cites] Pancreas. 2003 Apr;26(3):e48-54 [12657964.001]
  • [Cites] Cancer Biol Ther. 2002 May-Jun;1(3):293-6 [12432281.001]
  • [Cites] Am J Pathol. 2002 Nov;161(5):1541-7 [12414502.001]
  • [Cites] Mod Pathol. 2002 Oct;15(10):1087-95 [12379756.001]
  • [Cites] Gastroenterology. 2002 Oct;123(4):1052-60 [12360467.001]
  • [Cites] Am J Clin Pathol. 2002 Aug;118(2):194-201 [12162677.001]
  • [Cites] Am J Pathol. 2002 May;160(5):1573-81 [12000709.001]
  • [Cites] Mol Cell Biol. 2002 Jan;22(2):635-43 [11756558.001]
  • [Cites] Am J Surg Pathol. 2001 Aug;25(8):1047-53 [11474289.001]
  • [Cites] Am J Pathol. 2001 May;158(5):1677-83 [11337365.001]
  • [Cites] Cancer Cell. 2003 Dec;4(6):437-50 [14706336.001]
  • [Cites] Mod Pathol. 2003 Sep;16(9):902-12 [13679454.001]
  • [Cites] Cancer Res. 2003 Jul 1;63(13):3735-42 [12839967.001]
  • [Cites] Cancer Res. 2003 May 1;63(9):2005-9 [12727809.001]
  • [Cites] Am J Clin Pathol. 2002 May;117(5):791-6 [12090430.001]
  • [Cites] Am J Surg Pathol. 2001 May;25(5):579-86 [11342768.001]
  • [Cites] Clin Cancer Res. 2000 Aug;6(8):2969-72 [10955772.001]
  • [Cites] JAMA. 2000 Oct 18;284(15):1954-61 [11035892.001]
  • [Cites] Am J Pathol. 2000 Jul;157(1):83-92 [10880379.001]
  • [Cites] Am J Pathol. 2000 Jun;156(6):2123-33 [10854233.001]
  • [Cites] Am J Pathol. 2000 May;156(5):1767-71 [10793087.001]
  • [Cites] Cancer Res. 2000 Apr 1;60(7):2002-6 [10766191.001]
  • [Cites] Cancer Res. 2000 Apr 1;60(7):1835-9 [10766168.001]
  • [Cites] Cancer Res. 2005 Mar 1;65(5):1619-26 [15753353.001]
  • [Cites] Neoplasia. 2005 Jan;7(1):17-23 [15720814.001]
  • [Cites] Cancer. 1999 Apr 15;85(8):1703-10 [10223563.001]
  • [Cites] Ann Intern Med. 1999 Aug 17;131(4):247-55 [10454945.001]
  • [Cites] Ann Diagn Pathol. 1998 Oct;2(5):286-92 [9845751.001]
  • [Cites] Cancer Res. 1998 Oct 15;58(20):4740-4 [9788631.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 Jun;7(6):515-21 [9641496.001]
  • [Cites] Am J Surg Pathol. 1998 Feb;22(2):163-9 [9500216.001]
  • [Cites] Cancer Res. 1997 Aug 1;57(15):3126-30 [9242437.001]
  • [Cites] Cancer Res. 1997 Jun 1;57(11):2140-3 [9187111.001]
  • [Cites] J Natl Cancer Inst. 1997 Mar 19;89(6):442-6 [9091646.001]
  • [Cites] Science. 1996 Jan 19;271(5247):350-3 [8553070.001]
  • [Cites] Gastroenterology. 1996 Jan;110(1):227-31 [8536861.001]
  • [Cites] Nat Genet. 1994 Sep;8(1):27-32 [7726912.001]
  • [Cites] Cancer Res. 1994 Jul 1;54(13):3568-73 [8012983.001]
  • [Cites] Cancer Res. 1993 Mar 1;53(5):953-6 [8439969.001]
  • [Cites] Cancer. 1979 Apr;43(4):1418-28 [445339.001]
  • [Cites] Cancer Res. 1976 Jul;36(7 PT 2):2690-8 [1277176.001]
  • [Cites] Clin Gastroenterol Hepatol. 2004 Jul;2(7):606-21 [15224285.001]
  • [Cites] Am J Surg Pathol. 2004 Aug;28(8):977-87 [15252303.001]
  • [Cites] Gastroenterology. 2004 Jun;126(7):1674-80 [15188160.001]
  • [Cites] Cancer Res. 2004 Apr 1;64(7):2634-8 [15059921.001]
  • [Cites] Genes Dev. 2003 Dec 15;17(24):3112-26 [14681207.001]
  • [Cites] Mol Imaging. 2007 Mar-Apr;6(2):131-9 [17445507.001]
  • [Cites] Cancer Res. 2007 Aug 1;67(15):7068-71 [17652141.001]
  • [Cites] Am J Pathol. 2007 Jul;171(1):263-73 [17591971.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2007;14(3):243-54 [17520199.001]
  • [Cites] Am J Surg Pathol. 2007 Apr;31(4):645-6 [17414117.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Mar 13;104(11):4437-42 [17360542.001]
  • [Cites] Cancer Cell. 2007 Mar;11(3):291-302 [17349585.001]
  • [Cites] Cancer Cell. 2007 Mar;11(3):229-43 [17349581.001]
  • [Cites] Cancer Cell. 2007 Mar;11(3):211-3 [17349578.001]
  • [Cites] Cancer Res. 2007 Jan 15;67(2):433-6 [17234748.001]
  • [Cites] Gastroenterology. 2006 Dec;131(6):1844-55 [17087933.001]
  • [Cites] Genes Dev. 2006 Nov 15;20(22):3130-46 [17114584.001]
  • [Cites] Clin Cancer Res. 2006 Sep 15;12(18):5417-22 [17000675.001]
  • [Cites] Clin Cancer Res. 2006 Sep 15;12(18):5411-6 [17000674.001]
  • [Cites] Am J Surg Pathol. 2006 Sep;30(9):1067-76 [16931950.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2006;13(4):286-95 [16858539.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Jun;4(6):766-81; quiz 665 [16682259.001]
  • [Cites] Am J Surg Pathol. 2006 Jun;30(6):754-9 [16723855.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):1208-17 [16424060.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):242-7 [16397237.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):95-106 [16397221.001]
  • [Cites] Virchows Arch. 2005 Nov;447(5):800-5 [16021508.001]
  • [Cites] Int J Cancer. 2006 Jan 15;118(2):405-11 [16052519.001]
  • [Cites] N Engl J Med. 2005 Oct 27;353(17):1784-92 [16251534.001]
  • (PMID = 18787611.001).
  • [ISSN] 1936-2625
  • [Journal-full-title] International journal of clinical and experimental pathology
  • [ISO-abbreviation] Int J Clin Exp Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2480542
  • [Keywords] NOTNLM ; Pancreatic cancer / epigenetics / genetics / intraepithelial neoplasm / metaplasia
  •  go-up   go-down


90. Sandroussi C, McGilvray ID: Gastric venous reconstruction after radical pancreatic surgery: case report and review of the literature. J Gastrointest Surg; 2010 Jun;14(6):1027-30
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastric venous reconstruction after radical pancreatic surgery: case report and review of the literature.
  • Vascular resection during surgery for adenocarcinoma of the pancreas is being performed with increasing frequency in order to achieve an R0 resection.
  • We report the first case of left gastric vein to inferior mesenteric vein bypass during a radical total pancreatectomy with long-segment portal vein resection for pancreatic adenocarcinoma, performed to relieve severe gastric venous congestion.
  • [MeSH-major] Adenocarcinoma / surgery. Pancreatic Neoplasms / surgery. Stomach / blood supply. Vascular Neoplasms / surgery. Vascular Surgical Procedures / methods. Veins / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20387128.001).
  • [ISSN] 1873-4626
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 12
  •  go-up   go-down


91. Klöppel G, Sipos B, Lüttges J: [Spectrum of chronic pancreatitis. On the way to etiological classification]. Pathologe; 2005 Feb;26(1):59-66
MedlinePlus Health Information. consumer health - Pancreatitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A catalog of five criteria is presented for distinguishing chronic pancreatitis from ductal adenocarcinoma of the pancreas.
  • [MeSH-minor] Alcoholism / complications. Autoimmune Diseases / pathology. Chronic Disease. Humans. Incidence. Inflammation. Pancreas / injuries

  • Genetic Alliance. consumer health - Pancreatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterology. 1996 Jul;111(1):224-31 [8698203.001]
  • [Cites] Virchows Arch. 2004 Dec;445(6):552-63 [15517359.001]
  • [Cites] Nat Genet. 2000 Jun;25(2):213-6 [10835640.001]
  • [Cites] Hepatogastroenterology. 1982 Oct;29(5):198-208 [7173808.001]
  • [Cites] Gut. 1999 Apr;44(4):534-41 [10075961.001]
  • [Cites] Pancreas. 2003 Jul;27(1):14-9 [12826900.001]
  • [Cites] Am J Surg Pathol. 2001 May;25(5):579-86 [11342768.001]
  • [Cites] Histopathology. 2001 Feb;38(2):105-10 [11207823.001]
  • [Cites] Virchows Arch A Pathol Anat Histol. 1976 Aug 23;371(2):145-52 [824797.001]
  • [Cites] Gut. 1993 Mar;34(3):343-7 [8097180.001]
  • [Cites] Am J Surg Pathol. 2003 Aug;27(8):1119-27 [12883244.001]
  • [Cites] Hum Pathol. 1991 Apr;22(4):387-95 [2050373.001]
  • [Cites] Am J Surg Pathol. 2003 Mar;27(3):334-42 [12604889.001]
  • [Cites] Gut. 1997 Aug;41(2):263-8 [9301509.001]
  • [Cites] J Gastrointest Surg. 2003 Jan;7(1):129-37; discussion 137-9 [12559194.001]
  • [Cites] Virchows Arch. 2004 Jul;445(1):1-8 [15138818.001]
  • [Cites] Gut. 1985 Aug;26(8):825-33 [4018649.001]
  • [Cites] Dig Dis Sci. 1998 Mar;43(3):567-74 [9539653.001]
  • [Cites] Cancer. 2004 Jan 1;100(1):173-82 [14692038.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1992;420(1):1-4 [1539444.001]
  • [Cites] Surg Clin North Am. 1999 Aug;79(4):801-14 [10470328.001]
  • [Cites] Lab Invest. 2000 Jan;80(1):47-55 [10653002.001]
  • [Cites] Gastroenterology. 2001 Feb;120(3):682-707 [11179244.001]
  • [Cites] Int J Pancreatol. 1995 Dec;18(3):197-206 [8708390.001]
  • (PMID = 15586283.001).
  • [ISSN] 0172-8113
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


92. Wente MN, Schmied BM, Schmidt J, Büchler MW: [Differentiated therapy for intraductal papillary mucinous neoplasms]. Chirurg; 2009 Jan;80(1):7-13
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Intraductal papillary mucinous neoplasms (IPMN) of the pancreas are of increasing interest in the field of pancreatic surgery ever since their first description as an individual pancreatic tumor entity in 1982.
  • Invasive IPMN forms (carcinoma in situ and invasive carcinoma) and in particular noninvasive IPMNs (adenoma and borderline tumors) reveal significantly better survival rates than ductal adenocarcinoma of the pancreas.
  • [MeSH-major] Adenocarcinoma, Mucinous / surgery. Carcinoma, Pancreatic Ductal / surgery. Carcinoma, Papillary / surgery. Pancreatectomy / methods. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Carcinoma in Situ / diagnosis. Carcinoma in Situ / mortality. Carcinoma in Situ / pathology. Carcinoma in Situ / surgery. Humans. Magnetic Resonance Imaging. Neoplasm Invasiveness. Neoplasm Staging. Pancreas / pathology. Prognosis. Radiography, Dual-Energy Scanned Projection. Survival Rate. Tomography, Spiral Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Minerva Chir. 2004 Apr;59(2):185-207 [15238892.001]
  • [Cites] Radiology. 2008 Sep;248(3):876-86 [18632526.001]
  • [Cites] Gastroenterology. 2002 Nov;123(5):1500-7 [12404225.001]
  • [Cites] Am J Surg. 1999 Oct;178(4):344-7 [10587197.001]
  • [Cites] Gut. 2002 Nov;51(5):717-22 [12377813.001]
  • [Cites] Am J Surg Pathol. 2004 Aug;28(8):977-87 [15252303.001]
  • [Cites] Ann Surg. 2004 Jun;239(6):788-97; discussion 797-9 [15166958.001]
  • [Cites] Gut. 2008 Mar;57(3):287-9 [18268051.001]
  • [Cites] World J Surg. 2008 Oct;32(10):2253-60 [18668283.001]
  • [Cites] Arch Surg. 2008 Jul;143(7):639-46; discussion 646 [18645105.001]
  • [Cites] J Clin Gastroenterol. 2008 Mar;42(3):284-94 [18223495.001]
  • [Cites] Pancreatology. 2006;6(1-2):17-32 [16327281.001]
  • [Cites] Eur J Surg Oncol. 2007 Aug;33(6):678-84 [17207960.001]
  • [Cites] Am J Surg Pathol. 2001 May;25(5):579-86 [11342768.001]
  • [Cites] Am J Surg. 2005 May;189(5):632-6; discussion 637 [15862510.001]
  • [Cites] Gastroenterology. 2007 Jul;133(1):72-9; quiz 309-10 [17631133.001]
  • [Cites] Ann Surg Oncol. 2006 Apr;13(4):582-94 [16523362.001]
  • [Cites] Gut. 2007 Aug;56(8):1086-90 [17127707.001]
  • [Cites] Arch Surg. 1999 Oct;134(10 ):1131-6 [10522860.001]
  • [Cites] Ann Surg. 1997 Oct;226(4):491-8; discussion 498-500 [9351717.001]
  • [Cites] J Clin Gastroenterol. 2006 Oct;40(9):856-62 [17016145.001]
  • [Cites] Pancreas. 2004 Apr;28(3):241-6 [15084964.001]
  • [Cites] J Gastrointest Surg. 2003 Jan;7(1):12-8; discussion 18-9 [12559180.001]
  • [Cites] J Clin Gastroenterol. 2003 Mar;36(3):261-5 [12590239.001]
  • [Cites] Lancet. 2005 Jan 8-14;365(9454):153-65 [15639298.001]
  • [Cites] Ann Surg. 2007 Dec;246(6):966-74; discussion 974-5 [18043098.001]
  • [Cites] Am J Surg Pathol. 2000 Oct;24(10):1372-7 [11023098.001]
  • [Cites] Am J Surg Pathol. 1999 Jan;23 (1):1-16 [9888699.001]
  • [Cites] World J Surg. 2008 Feb;32(2):271-8; discussion 279-80 [18027021.001]
  • [Cites] Gut. 2008 Mar;57(3):339-43 [17660227.001]
  • [Cites] Ann Surg. 2001 Sep;234(3):313-21; discussion 321-2 [11524584.001]
  • [Cites] Cancer Control. 2008 Oct;15(4):322-33 [18813200.001]
  • [Cites] Ann Surg Oncol. 2008 Jan;15(1):199-205 [17909912.001]
  • [Cites] Gut. 2008 Nov;57(11):1490-1 [18941002.001]
  • [Cites] Am J Gastroenterol. 2008 Nov;103(11):2871-7 [18775021.001]
  • [Cites] J Gastrointest Surg. 2008 Mar;12(3):414-6 [17968632.001]
  • [Cites] Ann Surg. 2004 May;239(5):678-85; discussion 685-7 [15082972.001]
  • [Cites] Korean J Radiol. 2003 Jul-Sep;4(3):157-62 [14530644.001]
  • [Cites] J Clin Pathol. 2008 Dec;61(12):1303-13 [18703569.001]
  • [Cites] Gut. 2008 Nov;57(11):1561-5 [18477671.001]
  • [Cites] Nihon Shokakibyo Gakkai Zasshi. 2007 Sep;104(9):1338-43 [17827904.001]
  • [Cites] Ann Surg. 2004 Mar;239(3):400-8 [15075659.001]
  • [Cites] Gut. 2002 Jun;50(6):861-8 [12010891.001]
  • [Cites] Ann Surg. 2007 Oct;246(4):644-51; discussion 651-4 [17893501.001]
  • [Cites] J Gastrointest Surg. 2008 Mar;12(3):401-4 [17957438.001]
  • [Cites] J Gastrointest Surg. 2008 Jan;12(1):101-9 [17917784.001]
  • (PMID = 19082569.001).
  • [ISSN] 1433-0385
  • [Journal-full-title] Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 50
  •  go-up   go-down


93. Moore MJ, Tang P, Renouf D, Major P, Hedley D, Paterson V, Wang L, Dhesy-Thind B, Southwood B, Doyle L: A phase II study of Halichondrin B analog eribulin mesylate (E7389) as second-line therapy for patients with advanced pancreatic cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e15634

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of Halichondrin B analog eribulin mesylate (E7389) as second-line therapy for patients with advanced pancreatic cancer.
  • Preclinical studies suggest that Eribulin may be effective in pancreatic cancer.
  • The primary objective of this study was to determine the objective response rate (complete and partial) to Eribulin in patients with advanced, pancreatic adenocarcinoma that had progressed after gemcitabine based therapy.
  • METHODS: Eligibility criteria included histologically confirmed pancreatic adenocarcinoma; measurable locally advanced, or metastatic disease; disease progression after gemcitabine; and ECOG performance status 0-2.
  • CONCLUSIONS: Eribulin was well tolerated and did not result in any objective responses in refractory pancreatic cancer.
  • Further studies of eribulin in pancreatic cancer may be warranted.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962741.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


94. Melnikov AA, Scholtens D, Talamonti MS, Bentrem DJ, Levenson VV: Methylation profile of circulating plasma DNA in patients with pancreatic cancer. J Surg Oncol; 2009 Feb 1;99(2):119-22
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Methylation profile of circulating plasma DNA in patients with pancreatic cancer.
  • BACKGROUND AND OBJECTIVES: Detection of pancreatic cancer by blood-based test may improve outcomes.
  • We sought to establish the feasibility of a blood-based detection of pancreatic cancer through multiplexed array-mediated analysis of DNA methylation.
  • Methylation profiles in patients with ductal cell adenocarcinoma of the pancreas (n = 30) and healthy gender and age-matched controls (n = 30) were compared.
  • CONCLUSION: Differential methylation profiling of plasma DNA can detect ductal adenocarcinoma of the pancreas with significant accuracy and should be explored further.
  • [MeSH-major] Biomarkers, Tumor / blood. Carcinoma, Pancreatic Ductal / genetics. DNA Methylation. Pancreatic Neoplasms / genetics

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19065635.001).
  • [ISSN] 1096-9098
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Genetic Markers; 9007-49-2 / DNA
  •  go-up   go-down


95. Lequaglie C, Della Morte A, Feudale E, Giudice G: [Solitary metachronous metastasis of the sternum from pancreatic adenocarcinoma]. Chir Ital; 2007 Nov-Dec;59(6):901-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Solitary metachronous metastasis of the sternum from pancreatic adenocarcinoma].
  • [Transliterated title] Metastasi umica metacrona dello sterno da adenocarcinoma del pancreas.
  • Sternal metastases from adenocarcinoma of the pancreas are extremely rare, and even more so when solitary.
  • Two years earlier, the patient reported on here, a 67-year-old man with a solitary osteolytic lesion of the sternal manubrium, had undergone a duodeno-cephalopancreatectomy for adenocarcinoma of the pancreas (G2, pY3, pN1) followed by adjuvant radio-chemotherapy.
  • The histological examination revealed secondary adenocarcinoma with 3 mediastinal metastatic lymph nodes.
  • [MeSH-major] Adenocarcinoma / secondary. Bone Neoplasms / secondary. Bone Neoplasms / surgery. Pancreatic Neoplasms. Sternum

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18361001.001).
  • [ISSN] 0009-4773
  • [Journal-full-title] Chirurgia italiana
  • [ISO-abbreviation] Chir Ital
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


96. Link BC, Reichelt U, Schreiber M, Kaifi JT, Wachowiak R, Bogoevski D, Bubenheim M, Cataldegirmen G, Gawad KA, Issa R, Koops S, Izbicki JR, Yekebas EF: Prognostic implications of netrin-1 expression and its receptors in patients with adenocarcinoma of the pancreas. Ann Surg Oncol; 2007 Sep;14(9):2591-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic implications of netrin-1 expression and its receptors in patients with adenocarcinoma of the pancreas.
  • BACKGROUND: To assess the interaction between the expression of netrin-1 or of its receptors to the prognosis of ductal adenocarcinoma of the pancreas.
  • METHODS: In 82 patients with resectable pancreatic adenocarcinoma who underwent curative operation, the expression patterns of netrin-1, deleted in colorectal carcinomas (DCC), UNC5H3, and neogenin were determined by immunohistochemical staining.
  • CONCLUSION: Expression of netrin-1 has significant impact on time to tumor relapse in adenocarcinoma of the pancreas.
  • Netrin-1 expression is associated with worse outcome in poorly differentiated pancreatic adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / metabolism. Nerve Growth Factors / metabolism. Pancreatic Neoplasms / metabolism. Tumor Suppressor Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17549567.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Membrane Proteins; 0 / Nerve Growth Factors; 0 / Receptors, Cell Surface; 0 / Tumor Suppressor Proteins; 0 / neogenin; 0 / netrin receptors; 158651-98-0 / netrin-1; EC 2.7.11.17 / Calcium-Calmodulin-Dependent Protein Kinases
  •  go-up   go-down


97. Tomlinson JS, Jain S, Bentrem DJ, Sekeris EG, Maggard MA, Hines OJ, Reber HA, Ko CY: Accuracy of staging node-negative pancreas cancer: a potential quality measure. Arch Surg; 2007 Aug;142(8):767-723; discussion 773-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Accuracy of staging node-negative pancreas cancer: a potential quality measure.
  • OBJECTIVE: To determine the optimal number of lymph nodes to examine for accurate staging of node-negative pancreatic adenocarcinoma after pancreaticoduodenectomy.
  • DESIGN, SETTING, AND PATIENTS: Data from the National Cancer Institute's Surveillance, Epidemiology, and End Results program (1988-2002) were used to identify 3505 patients who underwent pancreaticoduodenectomy for adenocarcinoma of the pancreas, including 1150 patients who were pathologically node negative (pN0) and 584 patients with a single positive node (pN1a).
  • MAIN OUTCOME MEASURE: Examination of 15 lymph nodes appears to be optimal for accurate staging of node-negative adenocarcinoma of the pancreas after pancreaticoduodenectomy.
  • CONCLUSIONS: Examination of 15 lymph nodes appears to be optimal to accurately stage node-negative adenocarcinoma of the pancreas after pancreaticoduodenectomy.
  • Furthermore, evaluation of at least 15 lymph nodes of a pancreaticoduodenectomy specimen may serve as a quality measure in the treatment of pancreatic adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Neoplasm Staging / standards. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17709731.001).
  • [ISSN] 0004-0010
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


98. Ioka T, Takakura R, Nakaizumi A, Tanaka S, Iishi H, Nakamura S, Nishiyama K, Oohigashi H, Ishikawa O, Watanabe A, Mukai S: A multicenter randomized phase II study of full-dose gemcitabine and concurrent radiotherapy comparing gemcitabine alone for the unresectable locally advanced pancreatic adenocarcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):e15512

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A multicenter randomized phase II study of full-dose gemcitabine and concurrent radiotherapy comparing gemcitabine alone for the unresectable locally advanced pancreatic adenocarcinoma.
  • : e15512 Background: Some of locally advanced pancreatic cancers (LAPC) are considered to include a potential micro metastasis.
  • METHODS: Patients with histologically or cytologically proven pancreatic adenocarcinoma were eligible for this study.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962283.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


99. Coevoet H, Woelffle D, Quinton JF, Hector E, Bonnière X, Boruchowicz A: [Distal pancreatectomy for rectal metastatic adenocarcinoma 6 years after proctectomy]. Gastroenterol Clin Biol; 2007 Jun-Jul;31(6-7):624-6
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Distal pancreatectomy for rectal metastatic adenocarcinoma 6 years after proctectomy].
  • [Transliterated title] Pancréatectomie caudale pour métastase d'un adénocarcinome rectal 6 ans après exérèse de la tumeur primitive.
  • Diagnosis was made based on increased CEA levels following excision of the rectal tumor discovered during treatment follow up of liver and pulmonary metastases.
  • Pancreatic resection for metastatic colonic adenocarcinoma of the pancreas may be considered in selected patients without extrapancreatic disease.
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma / surgery. Neoplasms, Second Primary / surgery. Pancreatectomy / methods. Pancreatic Neoplasms / secondary. Pancreatic Neoplasms / surgery. Rectal Neoplasms / pathology. Rectal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17646794.001).
  • [ISSN] 0399-8320
  • [Journal-full-title] Gastroentérologie clinique et biologique
  • [ISO-abbreviation] Gastroenterol. Clin. Biol.
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


100. Brus C, Saif MW: Second line therapy for advanced pancreatic adenocarcinoma: where are we and where are we going? Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010. JOP; 2010;11(4):321-3
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second line therapy for advanced pancreatic adenocarcinoma: where are we and where are we going? Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010.
  • Most patients with adenocarcinoma of the pancreas present with locally advanced or metastatic disease.
  • These abstracts provide exciting new directions for the treatment of gemcitabine-refractory advanced pancreatic cancer.
  • [MeSH-major] Adenocarcinoma / therapy. Combined Modality Therapy / trends. Medical Oncology / trends. Pancreatic Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20601802.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 15
  •  go-up   go-down






Advertisement